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Abstract
Nanotechnology has enthused excessive expectations in recent years, particularly in the biology
and biomedical fields. Carbon-coated metallic nanomagnets reveal significant physicochemical
properties, which are referred to as superparamagnetism, that when designed appropriately can
be utilized to generate novel diagnostic and therapeutic applications for a wide range of
biologically hazardous species. Schistosomiasis is a chronic parasitic disease that can infect both
humans and animals, particularly cattle. It is caused by a trematode blood fluke of the genus
Schistosoma which belong to the schistosomatidae family. At least 200 million individuals are
infected in 75 countries while 600 million people are exposed to infection and are potentially
victim of this parasite. Schistosomiasis is still recognized as one of the most neglected disease,
the current available diagnostic techniques are deficient in accuracy and are incapable of
identifying the disease in its early stages. Moreover, they suffer from prolonged examination
time. Besides, the poorly available therapeutic drugs started to lose their efficacy and the parasite
started to develop resistance against most of them, which create an imperative need for
developing novel diagnostic and therapeutic tools. The humoral immune response of the
Camelidae is unique since these animals possess functional heavy-chain only antibodies in
addition to the classical antibodies. Thanks to recombinant DNA technology, a series of singledomain antigen binding entities can be produced against specific schistosome’s parasite antigens.
These binders possess a number of distinctive biophysical properties that offer particular
advantages in various theranostic applications. Finally, nanomagnetism was selected to represent
a certain phenomena through which we demonstrated, to our knowledge for the first time, the
successful construction of effective and functional bioconjugate system which is appropriate for
a plethora of diagnostic and therapeutic applications. The main thrust of this research work was
towards the developing of single domain antibodies against Schistosoma mansoni gut specific
antigen and execratory secretory antigen. In parallel, state-of-the-art methodologies were
implemented for constructing a bioconjugate system composed of sdAb and graphene-coated
metallic nanomagnet tagged with a carboxyl terminal. Finally, the well-established metastable
technetium-99 (99mTc) is used for labeling the conjugate for studying the possibility of active and
magnetic targeting of the nano-structured system – i.e. 99mTc-sdAb-Fe@C-MNP conjugates.

xv

Aim of this research
In this study, we aimed at studying the possibility of generating single domain antibodies
(hereinafter referred to as sdAb, VHH, Nb or Nanobodies®) against species-specific antigens of
Schistosoma mansoni for diagnostic and therapeutic applications. Our interest has been focused
on two antigens (i) S. mansoni Cathepsin B, and (ii) S. mansoni Execratory Secretory antigen.
Furthermore, proving the concept of constructing novel conjugate systems through a distinctive
bio-conjugation approach:


Constructing of sdAb-Metallic Graphene-Coated Magnetic Nanoparticles for a variety of
in vitro and in vivo diagnostic and therapeutic applications (i.e. TAT and MRI imaging,
active/magnetic targeting and magnetic hyperthermia).

Specific objectives of the study
First Chapter:


Camel immunization with Schistosoma mansoni native antigens of Cathepsin B (SmCB)
and secretory execratory (SmES).



Construction of Nanobody® immune cDNA and phage display libraries.



Generation of SmCB binding Nanobodies®



Generation of SmES binding Nanobodies®



Characterization of Nb-Ag binding interaction via ELISA assays

Second Chapter:


Generation of Nb-Graphene-Coated MNP



Radio-labeling of Nb-Graphene-Coated MNP system and studying of magnetic targeting

Concluding Remarks and Future Challenges

xvi

CHAPTER 1: GENERATION OF CAMELIDAE’S SINGLE-DOMAIN
ANTIBODIES AGAINST Schistosoma mansoni
1 Schistosomiasis: The Disease and the Cure
1.1 Background
Schistosomiasis is a parasitic disease commonly known as bilharzia, the infection caused by one
of the five different species of the parasite (trematode helminthes) of the genus Schistosoma. The
species of prevalent seriosity are S. haematobium (dominant in Africa), S. japonicum (dominant
in Japan, Southeast Asia and Western Pacific) and S. mansoni (dominant in Africa, Southwest
Asia, Brazil and Caribbean). Schistosoma intercalatum and S. mekongi are recognized as the two
less significant species that parasitize humans. The route of infection takes place during direct
skin contact with the free-swimming stage (i.e. cercariae) while swimming or bathing in slowmoving fresh water streams which are inhabited by intermediate host (Adel, 2001).
The world health organization WHO estimates that there are about 200 million people
worldwide infected with Schistosomiasis, 120 million symptomatic patients and 600 million
individuals live at risk (WHO, 1993). In sub-Saharan Africa the estimated fatality related to S.
mansoni and S. haematobium is about 280,000 people per year (Pearce & MacDonald, 2002).
The range of endemicity of the disease may change either throughout movements of infected
persons to endemic areas, or through the creation of artificial new habitat for infected snails (i.e.
dams, canals and fields irrigated by flooding, for instance, rice fields).
Schistosomiasis is endemic to over 70 countries, and about 85% of the 200 million
people infected with schistosoma live in Africa (WHO, 2010). Figure 1.1 represents the recent
distribution of the diseases worldwide and primarily highlighting the following regions:


Africa: Southern, Sub-Saharan, Lake Malawi.



Asia: Philippines, Laos, Cambodia, Japan, Central Indonesia, Mekong Delta,
Southern China.



Caribbean: Antigua, Dominican Republic, Guadeloupe, Martinique, Montserrat, Saint
Lucia.



Egypt: Nile River Valley.



Middle East: Iran, Iraq, Saudi Arabia, Syrian Arab Republic, Yemen.



South America: Brazil, Suriname, Venezuela.
1

Figure 1.1. Geographic Distribution of Schistosomiasis. (CDC, 2011)
There are four trematode species in the genus Schistosoma, Schistosoma mansoni, S.
haematobium, S. japonicum, and S. mekongi, cause a series of related diseases in humans
referred to as schistosomiasis. Additionally, S. intercalatum is a parasite of cattle in West Africa
which occasionally causes the disease in humans. Schistosomiasis is also known as: Katayama
fever, Bilharzia or Schistosome blood-dwelling fluke worms.
The effect of Schistosomiasis on human health was early characterized at least 4,000
years ago in early Egyptian papyri, recent analysis could reveal immunological clues as to its
existence in ancient mummies (Adel, 2001). In 1851, Theodor Bilharz discovered the etiology of
Schistosomiasis in humans while he was working out of Cairo, Egypt. The German physician
successfully identified adult male and female Schistosoma haematobium during autopsy
examinations. Furthermore, for more than half a century the clinical symptoms of Schistosoma
japonicum was described as a syndrome until the species was discovered in 1904.
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In 1907, Sir Patrick Manson was the first scientist who discovered Schistosoma mansoni
and could identify the differences in egg morphology – i.e. terminal versus lateral spine, and
excretion pathways – i.e. fecal versus urinary, of the two separate species S. mansoni and S.
haematobium. The life cycle details of S. japonicum were clearly elucidated in 1913 by
Keinosuka Miyairi and Masatsuga Suzuki, they could describe the route of infection into human
hosts and the exact dynamics of the parasite life cycles (Bigwan et al., 2012).
The life cycles of all schistosoma species are quite comparable, all the adult worms live
in mesenteric venules nearby liver, with the exception of S. haematobium in which adults
migrate to urinary bladder and live in venous plexus, where it discharges eggs into fresh water
sources through urine. All the species share the same mode of infection, infection starts in fresh
water where snails are shedding cercaria – i.e. infective form, which penetrates the patient skin –
e.g. human and cattle, after that cercaria develop into schistosomula which migrates to the lung.
Afterward, schistosomula continue to migrate to the liver through the blood stream. Finally, the
eggs enter the small intestine and excreted in the feces and deposited in fresh water where they
hatch and release miracidium that penetrate snails.
The schistosomes feed on their host blood (blood fluke) and are attached to the
mesenteric venous plexus. The females secrete eggs with ciliated miracidium larva in the urine
or stool. The miracidia are released from eggs, and they start to search for their related
freshwater snails that serve as the intermediate host. Subsequently, the infected snails produce
thousands of cercariae which remain in the water for months. Rivers, lakes, ponds, man-made
reservoirs and flooding irrigation systems become typical sources of infection and have resulted
in regional increases in schistosomiasis. On finding a host, the cercariae penetrate the host skin
and migrate into the liver where they transform into young worms over several weeks before
migrating to the mesenteric destination (WHO, 2010). Figure 1.2 illustrates the general life
cycles of the three widespread schistosoma species – i.e. Schistosoma mansoni, S. haematobium,
S. japonicum.
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Figure 1.2. Life Cycle of Schistosoma mansoni, S. haematobium, S. japonicum. (CDC, 2010)
There are three genera of freshwater snails which host miracidia of the key human
schistosomes, Oncomelania (S. japonicum), Bulinus (S. haematobium) and Biomphalaria (S.
mansoni). Schistosoma japonicum has competent reservoirs in many domesticated animals
including cats, dogs, horses and cattle. Whereas, S. haematobium has no identified animal
reservoirs, recently S. mansoni has been found to rarely parasitize monkeys and some rodents,
but does not have any genuinely established non-human hosts (Pearce & MacDonald, 2002).
Symptoms differ with respect to the infectious species of worm as well as the phase of
infection. In the very beginning, itching and rash at site of percutaneous penetration of the
cercariae is often recognized as the earliest sign of infection (usually known as Swimmer's Itch).
Immediately afterward, fever, localized oedema and allergic reactions may occur (John & Petri,
2006). The invasion of cercariae might initiate a wide variety of pathologies, the acute pathology
also known as Katayama fever which is very common in tourists, travelers and other people
accidentally exposed to transmission that include sudden fever, myalgia, fatigue and malaise.
Figure 1.3 illustrates the foremost symptoms of cercariae penetration (i.e. Swimmer's Itch).
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Figure 1.3. Initial Symptoms of Cercariae Penetration (Education, 2011)

The acute phase is usually manifested after one to three months of infection, when the
mature flukes start laying eggs in the mesenteric or vesical venules, patients start on complaining
of fever and abdominal pain. The deposition of eggs in the small hepatic venules causes the
formation of granulomas in the liver and initiation of pipestem fibrosis of the portal and
associated veins. Later on, hepatosplenomegaly and lymphadenopathy usually occur (Pearce &
MacDonald, 2002; Bigwan et al., 2012).
Chronic schistosomiasis stages may be presented in a wide variety of forms, intestinal
chronic schistosomiasis typically caused by S. japonicum and S. mansoni, where large intestines
are habitually the site of the infection. Patients experience diarrhea with or without blood,
dyspnoea, weight loss, diffuse abdominal pain and discomfort and hepatosplenomegaly might
occur. However, the main lesions (situated in large bowl and rectum, bladder, kidney and liver)
are not due to the worms but due to the trapped eggs in tissues secreting proteases that provoke
eosinophylic inflammatory and granulomatous reactions. Figure 1.4 shows 6-year-old boy with
gross reactive hepatosplenomegaly (left side) and 19-year-old symptomatic man (right side) with
chronic fibrotic hepatic schistosomiasis, it illustrate sever splenomegaly, external varices, ascites,
and growth retardation (Gryseels et al., 2006).
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Figure 1.4. Intestinal and Hepatic Schistosomiasis (Gryseels et al., 2006)
Urinary chronic schistosomiasis, typically caused by S. haematobium, is associated with
painful urination (dysuria). Given that, these eggs rupture the bladder wall and cause the damage
that can contribute to blood in urine (haematuria). In addition, they are also associated with
greatly increased incidence of squamous cell carcinoma of the bladder. Cerebral schistosomiasis
is most commonly caused by S. japonicum, in which the egg deposits cause local damage and
lesions in the host central nervous system (CNS). Moreover, severe problems rooted in capillary
blockage and subsequent ischemia (John & Petri, 2006). Figure 1.5 represents two different
urine samples, the right sample is for normal patient, whereas, the left sample is for a patient
with macro-haematuria due to ulceration of the bladder wall in urinary schistosomiasis (Gryseels
et al., 2006).

Figure 1.5. Haematuria Urinary Schistosomiasis (Gryseels et al., 2006)
Hepatic chronic schistosomiasis can lead to liver fibrosis, gastrointestinal varices. The
genital schistosomiasis, which is quite common in endemic areas, is regularly found in travelers
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and might lead to haemospermia or ovarian lesions causing infertility. However, in
schistosomiasis the organ function and indices remain largely unaffected for a long time when
the infection might no longer be detectable. Many of the unspecific and multifactorial morbidity
symptoms are clinically and epidemiologically hard to differentiate from other infections such as
malaria or other poverty-related health problems. Finally, quite a lot of other disorders are
usually associated with chronic schistosomiasis, the risk of colon and liver cancer increases with
prolonged infection. It is also possible that the chronic bacterial (e.g. chronic salmonellosis) and
trematodes infections are more than accidentally connected (John & Petri, 2006; WHO, 2010;
Bigwan et al., 2012).

1.2 Diagnosis and Therapy
1.2.1

Diagnostic Tests

The classical standards of diagnosing schistosomiasis are still microscopic-based examination of
excreta – i.e. urine and stool smears. Nevertheless, concentration steps need to be included for
mild infections or poor egg secretions. Unfortunately, the egg count poorly reflects the worm
burden inside the host. Nevertheless, bladder or rectal biopsy specimens are also standard
practice (Elliott, 1996). Recently, some haematological techniques correlate between the
elevated count of eosinophil and schistosomiasis infection (Dajotoy et al., 2004).
Additionally, sensitive antibody-based assays – i.e. methods where the schistosomesspecific host antibodies are detected, are available. However, these approaches are restricted to
specialized hospital settings and fail to discriminate exposure to antigens from active infections.
Likewise, antibody tests are also available, such tests are able to screen the presence and quantify
the somatic schistosomes’ antigens as well. Commonly, circulating anodic antigen – CAA and
circulating cathodic antigen – CCA with monoclonal antibodies (mAbs) are successfully used.
Despite the fact that, such screening tests do not distinguish between present and history
infections (Fulford & Keystone, 2002).
1.2.2

Management and Therapy: Current Status and Novel Approaches

Bilharzia is treated symptomatically with various corticosteroids, a number of schistosomytoxic
compounds currently exist such as: Praziquantel, Oxamniquine and Artemisinin. Regarding
Praziquantel, it has insignificant toxicity to the animals and human while it exhibits an adequate
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toxicity to the mature worm stage, it prevents worms from growing or multiplying in the body.
Nonetheless, it is ineffective against immature stages, so that constant treatments are
compulsory, although, recurrences of infection still highly probable. The imminent threat of an
omnipresent resistance of helminthes to the only available drugs might happen, for this reason,
prolonged and massive treatment with these drugs should be avoided. Indeed, Oxamniquine
resistance has already been reported and Praziquantel tolerant schistosomes could be found in
animals (King et al., 2000).
In 2009, a notable study of the genome of the blood fluke Schistosoma mansoni (and S.
japonicum as well) was published, in which the entire 363 mega-base nuclear genome of the
blood fluke was fully analyzed, this genome encodes at least 11,809 genes (Berriman et al.,
2009). The bioinformatics approaches could successfully identify numerous metabolic
chokepoints, in addition, via thorough chemogenomic screens a series of the parasite proteins,
for which existing and future drugs may be effectively developed, has been pinpointed. Thus,
such information provides a giant resource for the research community from countless aspects in
order to develop new control tools, early diagnostic methodologies and therapeutics for the
eradication of this serious, and yet, neglected disease.
Without delay, it is clear that there is an urged need for developing totally new and potent
anti-schistosomes drugs, as well as, novel and sensitive diagnostic tools either applicable in field
tests or to mass-screening the worm burden in vivo in human and cattle. Nevertheless, identifying
the worm location in patients is greatly required and would positively affect the entire process of
developing robust, efficient, reliable and cost friendly theranostic endeavors. For these
objectives, the research group set a plan up to developed highly specific, soluble, stable and
monovalent single-domain antibodies (sdAbs) from immunized camel’s library against
Schistosoma mansoni parasite – i.e. fully functional antibody fragment. Comprehensive
enlightenment of the reasons behind selecting such unique antibody type is concluded from
studying their exceptional properties which will be resourcefully described in the next section.
Furthermore, a proof of concept experiment was developed for constructing of bioconjugate
system of radio-labeled graphene-coated metallic magnetic nanoparticles to various sdAbs for
diagnostic and therapeutic applications.
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2 Camelidae’s Single-Domain Antibodies: Current Status & Numerous Possibilities
2.1 Introduction
The intensity of the natural immune system has gained much interest because of its importance
in a wide range of both fundamental and applied sciences. The immunoglobulins are soluble
glycoproteins in blood and tissue liquids that play a basic and essential role in the humoral
immune system of vertebrates. Antibodies are synthesized by B-lymphocytes in response to
foreign biological and chemical substances – i.e. antigens, of enormous structural variations with
an intention to counteract, or neutralize, them. Owing to their high specificity and high binding
affinity of antigens and to the possibility of generating antibody against practically limitless
repertoire of antigens, antibodies and their derivatives are recognized among the most imperative
reagents for fundamental, applied and medical research (Tillib, 2011).
Notwithstanding the fact that camelids are economically important in the Middle East,
North African and South American countries, their immune system was barely investigated until
the mid-1990s. Systematically, camelid species belong to the family of Camelidae, suborder of
Tylopoda, order of Atiodactyla (Conrath et al., 2003). Table 1.1 gives an idea about the normal
average haematological values of camelid sera, in which it is so observable there are no
significant disparities among different camelidae species.
Table 1.1. Haematological values of camelid sera (Wernery et al., 1999)
Desert dromedary

Bactrian camel

Llama

Platelets

240-310 x 103/µL

Not available

240-310 x 103/µL

Red blood cells

7.1-10.9 x 106/µL

10.2-13.2 x 106/µL

10.5-17.2 x 106/µL

White blood cells

10.2-21.5 x 103/µL

10.0-15.8 x 103/µL

8.0-21.4 x 103/µL

Neutrophils (%)

35-60

28-83

41.7-72.9

Lymphocytes (%)

29-55

19-56

9.2-23.2

Monocytes (%)

2-5

0-7

0-4.6

Eosinophils (%)

2-12

0-18

0.2-21.4

Basophile (%)

0-2

0-3

0-14

Although various kits are in use to estimate the actual immunoglobulins concentration,
they generally fail to concede consistent results (Wernery, 2001). Therefore, it is rather
premature to propose a standard table with a reliable range of concentrations of the various
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immunoglobulins’ isotypes, and only a qualitative description can be merely provided.
Nevertheless, the average values from the few published data affirm that the dromedary
immunoglobulins-G IgG includes (i) IgG1 fraction purified from sera by protein A and protein G
chromatography of approximately 3 mg antibody per mL serum (Hamers-Casterman et al.,
1993), (ii) the IgG2 and IgG3 fractions’ concentrations are about 1 and 2 mg antibody per mL of
serum, respectively (Nguyen et al., 2001).
Classification of the camelid IgG is typically achieved based on the subject of
characteristic differences in the ranges of their heavy chain molecular weight’s values.
Epigrammatically, the conventional IgG1 is a dominant isotype of IgG antibodies comprising of
two heavy chains (H-chains) of about 50 kDa each, and two light chains (L-chains) of 25 kDa
each. The other two IgG fractions were named IgG2 and IgG3 which represent the camelid
heavy chain antibodies. The absence of the constant heavy chain domain (CH1-domain) which
was confirmed via complementary DNA (cDNA) analyses explains the H-chain molecular
weight difference of the IgG2 and IgG3 weighed against IgG1. Characteristically, the H-chains
of IgG2 and IgG3 are about 10 kDa lighter than those of the conventional IgG1 (De Genst et al.,
2006a).
The average concentration of the IgG2 and IgG3 in the serum of camelids is different for
each species. For instance, in dromedary approximately half of the concentration of the serum
IgG repertoire corresponds to the heavy-chain antibodies. However, their concentration in llama
serum is much lower (Muyldermans et al., 2001a; De Genst et al., 2006a).

2.2 Heavy Chain only Antibodies: Discovering the Phenomena
In 1993, a Belgian scientific group could find, by serendipity, (in the course of performing a set
of electrophoretic analysis of immunoglobulins for the sera of assorted representatives of
camelidae’s), that these animals incorporate in their serum a unique class of antibodies that lack
L-chains in presence of the conventional ones, they were called heavy-chain only antibodies
HCAbs (Hamers-Casterman et al., 1993). The antigen-binding domains of these exceptional
camelid HCAbs consist of only one domain, termed variable domain of the heavy chain of the
heavy-chain antibodies VHH. Such feature offers a large number of technological advantages in
the generation of engineered antibodies, as compared with conventional antibodies which require
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both the variable domain of the heavy chains (VH), in addition to that of the light chains (VL) to
bind their specific antigen appropriately (De Genst et al., 2006b).
The innate supremacy of HCAbs together with their small size, ability to recognize
unique epitopes, sub-nanomolar binding affinity, outstanding solubility, great stability, high
expression yields and scalable production in broad variety of expression systems have combined
together to make them an interestingly useful class of biomolecules for various medical
diagnostic and therapeutic applications.

2.3 The Camelidae HCAbs: Originality and Unique Features
The presence of such unique type of intrinsic antibodies as a component of the humoral immune
system is well established, not only for camelidae’s species but also for an assortment of other
animals. For instance, several notable studies were able to confirm the occurrence of distinctly
unconventional antibodies in the serum of wobbegong sharks (Orectolobus maculatus), nurse
sharks (Ginglymostoma cirratum) and in ratfish as well (Greenberg et al., 1995; Nuttall et al.,
2001). However, in these cartilaginous fishes they are commonly known as the IgNARs (Ig new
antigen receptors). The original nature of IgNARs is visible in their gross structure organization.
Nonetheless, HCAbs in sharks have a fairly different structure compared to camelidae’s, they are
disulfide-bonded homodimers consisting of five constant domains and one variable domain, this
single variable domain V-NAR is responsible for targeting antigens (Nuttall et al., 2001). Given
that, all the work in this research study have been carried out while utilizing only camelidae
HCAbs, from now, only details about camelidae’s will be discussed in an ample level of details.
2.3.1

Originality: Introduction

In the beginning, it was strongly suggested that these distinctive camelidae HCAbs will suffer
huge deficiency in engendering an extensive antigen-binding complexity. Plausibly, the
expansion of conventional forms of antibodies repertoire is formed, at first, by the random
association of heavy and light chains. Conversely, the prominent study established by HamersCasterman et al. could primarily analyze the immune response of naturally infected dromedaries,
with Trypanosoma evansi, in which a very diverse HCAbs response against different natural
proteins of the parasite was confirmed (Hamers-Casterman et al., 1993). Later and without a
doubt, numerous studies could establish the possibility to generate diverse HCAbs that can target
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a wide range of antigens (Cortez-Retamozo et al., 2004; De Genst et al., 2006b; Klooster et al.,
2007). It can be speculated that, the high frequency of mutation hotspots and the extended
structural repertoire of antigen-binding loops along with the longer complementary determining
regions (CDRs) contribute to the complexity of VHHs repertoire and balance, in some way, for
the lack of the combinatorial diversity between the heavy and light chains (Nguyen et al., 2000).
Unlike the pathological case of heavy-chain disease in which conventional antibodies
devoid of L-chains, these abnormalities are generated due to unusual deletion of large and
various parts of the VH and CH1. As a result, they fail to bind antigen properly and are
recognized as non-functional antibody fragments (Seligmann et al., 1979). In contrast, the
camelid HCAbs evidently contribute to the immune response of the camelidae species during the
course of infections. Thus, the VHHs derived from camelid HCAbs are fully functional and
active in antigen recognition. In addition, their inherent features make them superior to other
engineered variable heavy chains VH antigen-specific fragments from murine or human origins.
In conclusion, there have been relatively few studies that could successfully isolate
functional domains of VH from conventional antibodies (Tanaka et al., 2003) with the intention
of minimizing their sizes, however their practical implementation was usually mired by the low
antigen-binding affinity, poor solubility, low expression yields and unfavorably limited stability
features (Davies & Riechmann, 1995).
2.3.2

Original Amino Acids Sequence

In camelidae’s, despite the fact that the VH and VHH are similar, to a certain extent, in their
amino acid sequence, the most evident and reproducible remarkable distinction between the VH
and VHH comes from the substitution of four amino acids in the framework-2 region. Such
substitution is responsible for providing the VH with more hydrophobic characteristics – i.e.
anchoring place for VL, than the VHH in which all the replaced amino acids residues are
relatively more hydrophilic. Precisely, the VH’s highly conserved residues Val37, Gly44, Leu45,
and Trp47 are substituted in VHH by Phe37 (or Tyr37), Glu44 (or Gln44), Arg45 (or Cys45) and
Gly47 (or Leu47), as per Kabat numbering (Muyldermans, 2001b; Conrath et al., 2001a; De
Genst et al., 2006b).
Compared to humans, camelidae’s VHH amino acid sequence closely resembles that of
human’s VH of family III. Nevertheless, there are still some notable differences in its
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framework-2 and CDRs regions (Muyldermans et al., 1994; Vu et al., 1997; Harmsen et al.,
2000). As for the framework-2 region, the hydrophobic and highly conserved residues Val42,
Gly49, Leu50 and Trp52 of the human and also of mouse VHs’ are substituted in VHHs by
Phe42 (or Tyr42), Glu49, Arg50 (or Cys50), and frequently Gly52. However, these substitutions
do not induce any momentous conformational rearrangements of the molecular backbone as
revealed by many crystallographic analyses (Muyldermans et al., 2001a).
The conversion of hydrophobic surface into a more hydrophilic one will certainly resist
the preserved-native hydrophobic pairing with the VL (Chothia et al., 1985). Subsequently, the
natural existence of highly conserved hydrophilic substitutions will, by all aspects, enhance the
solubility of the isolated VHH domain compared to classical antibodies. Indeed, grafting these
camelidae’s VHH hallmark residues onto the murine or human single domain VH (a process
called ‘camelization’) would render the domain more soluble (Davies & Riechmann, 1994). This
can explain the low immunogenicity of VHHs which primarily originates from their small size,
in addition to the high homology between them and human VH of family III. Considerable
bioinformatics’ studies confirmed the occurrence of about 80-90% homology (Desmyter et al.,
1996). Moreover, a remarkable study by Vincke and colleagues reported successful
humanization of camelidae’s derived VHHs without compromising neither their specific function
nor their antigen-binding kinetics (Vincke et al., 2009).
2.3.3

Unique Features: Ontogeny vs. Structure and Functionality

The structure of HCAbs’ is quite unique, the whole molecule is composed of a single variable
domain, in which the hinge region and the two constant domains CH2 and CH3 are homologues
to those from the classical antibodies. HCAbs are naturally devoid of light chains and also lack
the first domain of the constant region CH1 of conventional antibodies. The variable domain of
the HCAbs represents the anchoring site for the constant CH2 and CH3 domains. Moreover, the
absence of the three antigen-binding loops provided by VL of VH reasonably authenticates the
responsibility of the VHHs’ hypervariable loops for antigen recognition. Hence, there was a
priori no reason to question the protruded elongation of the hypervariable regions, particularly
the CDR1 and CDR3, in VHHs more than in VHs (Muyldermans et al., 2009).
CDRs of HCAbs are very distinctive, the first amino acid of CDR1 is highly variable (Vu
et al., 1997; Nguyen et al., 2000). In addition, the CDR3 loop of VHH contains longer loops (i.e.
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in average 16-18 amino acids) than the same CDR of human VH (14-12 amino acids) or mouse
VH (7 amino acids) (Muyldermans et al., 2009). The high frequent tethering by an inter-loop
disulfide bond, typically between CDR1 and CDR3, (Muyldermans et al., 1994; Harmsen et al.,
2000) possibly responsible for assisting in the unique loop structure (Muyldermans, 2001b). In
summary, the presence of the additional intra-domain disulfide bond (connecting CDR3 and
CDR1 or CDR1 and CDR2) may have two outcomes: (i) anchoring the CDR3 against the former
interface and (ii) predispose the orientation of CDR3 for appropriate presentation to the antigen
(Bond et al., 2003).

Figure 1.6. Schematic Presentation of the Camelid Conventional and Heavy-Chain IgGs and
the Antigen-Binding Fragments thereof. A. From left to right, the composition of a classical
antibody (left), a heavy-chain antibody (middle) and a single-domain antigen-binding entity
derived from a heavy-chain antibody, the VHH (right). B. The sequence organization of the VH
and VHH with framework and CDR’s is schematically represented at the top of this panel
(Muyldermans et al., 2009). C. The VHH three complementarity determining regions (CDRs) of
the antigen-binding paratope are depicted as colored loops: CDR1 red, CDR2 green, and CDR3
blue. (Wesolowski et al., 2009)
The absence of the CH1 Region in VHH while their sequence is present in the genomic
DNA signifies that the CH1 sequences are removed during splicing due to a point mutation at the
5’ end of the CH1-hinge intron – i.e. at the 3’ end of the CH1 exon (Nguyen et al., 1999).
Understandably, the instantaneous secretion of camelid HCAbs may account for this absence. In
conventional antibodies, the major function of the CH1 domain is to serve as binding site for the
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H-chain chaperoning protein BiP, which prevents the secretion of the premature antibody from
the endoplasmic reticulum (ER). Once the BiP is replaced by the light chain the mature
antibodies are secreted (Hamers-Casterman et al., 1993).
Finally, the presence of the fragment crystallizable region Fc part of the camelidae’s
HCAbs explicates their ability to exert effector functions for target cell destruction through
various means: (i) antibody dependent cell-mediated cytotoxicity (ADCC), (ii) antibody
dependent cellular phagocytosis (ADCP) and (iii) complement dependent cytotoxicity (CDC)
typically as the conventional antibodies (Atarhouch et al., 1997; Nguyen et al., 1999; Chan &
Carter, 2010).
2.3.4

Unique Features: Higher Stability, Solubility and Binding Affinity

The remarkable high stability and the ability of refolding of VHHs make them an exceptionally
potential agent for numerous possibilities where harsh conditions are habitually encountered.
After prolonged heat treatment at relatively elevated temperatures (e.g. 70 ⁰C and 90 ⁰C), the

VHHs demonstrate high thermotolerance and unique ability to retain more than 80% of their
original binding affinity (Van der Linden et al., 1999; Ladenson et al., 2006). Moreover, VHHs
exhibit superior degradation-resistance when they exist with various types of protease (protein)
enzymes (Hussack et al., 2011). Additionally, VHHs reveal highly stable to extremes pH ranges,
Dumoulin and his colleagues confirmed that VHHs could preserve their binding affinity to their
target antigens at fairly high concentrations of chaotropic agents (Dumoulin et al., 2002). Such
unique feature might endow with ultimate promises for the production of new-fangled generation
of oral antibody therapy. Not only the presence of intra-domain disulfide bonding between the
CDRs is the reason behind their outstanding stability features, additionally is owed to their gifted
ability to properly refold after enforced unfolding in case they are exposed to different thermal or
chemical denaturation – e.g. high temperature, urea and guanidinium chloride (Dumoulin et al.,
2002; Ladenson et al., 2006).
Solubility, VHHs can be concentrated up to 10-20 mg/mL without any significant
aggregation, their superior solubility is partially dependent on the amino acid adaptations in their
framework-2 which grant them more hydrophilic characteristics than other VHs (Muyldermans
et al., 1994; Vu et al., 1997). The well-conserved hydrophobic VH residues which represent the
binding site with the light variable domain VL are responsible for the aggregation tendency of
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VHs when existing in aqueous solutions – i.e. to minimize the whole system free energy. In
sharp contrast, VHHs’ residues are replaced with more hydrophilic ones (Maass et al., 2007). It
is worth mentioning that these residues substitutions are encoded in the germline, and do not
occur during somatic hyper-mutation (Nguyen et al., 1998). In addition to the residual
substitution some other mechanisms are responsible for increasing the solubility of VHHs. For
instance, the CDR3 loop folds over the hydrophobic region and shield it from aqueous
environment (De Genst et al., 2006b).
Numerous reports deep-rooted the fact that isolated VHHs from immunized libraries
often have high binding affinity in the low nanomolar to sub-nanomolar ranges although it was
thought that the lack of the VL chain may negatively affect the affinity of VHH in which the
antigen-binding site is formed only by a single domain, thus it possesses only three CDR-loops
for antigen binding. Consequently, it was expected that the paratope of VHHs would have a
lower antigen-binding performance than that of conventional Antibodies (Cortez-Retamozo et
al., 2004; Klooster et al., 2007). Moreover, their functional affinities – i.e. avidity, can be tailored
for the favor of increasing its value to the optimal limit by constructing bi and multi-valence
super molecules (Goldman et al., 2006; Verheesen et al., 2006). In general, VHHs’ libraries
generated from immunized camelids retain full functional diversity, with high-affinity antigen
binding domains that can be isolated through screening a limited number of clones from immune
libraries without prior selection using display technologies (Harmsen et al., 2005; De Genst et
al., 2010).
2.3.5

Unique Features: Unconventional Epitope Recognition

VHHs are the smallest known protein fragments with the ability to specifically recognize an
antigen, these intact antigen-binding fragments measure about 2.4 nm in diameter and 4 nm
height. These nanoscale characteristics that made Ablynx laboratories in Belgium call them
Nanobodies®. The structural organization of the VHHs is comparable to that of the conventional
VH with an Ig fold of two β sheets, one of four strands and one of five strands (Muyldermans et
al., 2009).
In conventional antibodies, the paratope – i.e. the antigen-binding site, is composed of
both the heavy and light variable domains VH and VL (see Figure 1.6A). Despite the fact that,
in quite few cases, the heavy chain alone can also bind some antigens (Utsumi & Karush, 1964).
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The nature of such paratopes’ topography does not go well with the antigens’ epitopes with
grooves or concaved structures. They are either a flat surface or a concave surface which is
intimately similar to the cleft in the active sites of enzymes. As a result, the paratopes of
conventional antibodies generally evade targeting clefts, the lock and key theory usually plays a
critical role in many biological courses of actions. For example, almost all enzymatic reactions
are based on the interactions between molecules (Lakowski et al., 1996). Hence, conventional
antibodies are hardly ever recognized as competitive enzyme inhibitors or activators.
The VHHs’ paratope is enlarged via extensions of CDR1 and CDR3 loops which are
usually longer than that found in conventional antibodies. Additionally, the hypervariable loops
of the VHH seem to vary substantially in conformation and length from the corresponding loops
in VH of human and mouse (Nguyen et al., 2000; Decanniere et al., 2000). The longer CDR3
region of the VHH possesses the extraordinary capacity to form finger-like extensions that
protrude into antigen cavities, (see Figure 1.7), which will result in new antigen binding modes
and put forward the VHHs to act as ideal enzyme inhibitors or activators (Wesolowski et al.,
2009). A considerable fraction of camelid VHHs, were developed against various enzymes, for
instance, α-amylase, carbonic anhydrase and lysozyme, where they could act as target substrate
and competitively inhibit the target enzymes (Lauwereys et al., 1998; De Genst et al., 2010).

Figure 1.7. 3D-structures of Enzyme-Inhibiting sdAbs Derived from Camel HcAbs and Mouse
Fv. The three CDR loops are color-coded as: CDR1 red, CDR2 green, CDR3 blue. A. Chicken
lysozyme in complex with an inhibitory camel VHH. B: Chicken lysozyme in complex with the VL
and VH domains of a mouse mAb (Wesolowski et al., 2009)
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Persuasively, the small size and the longer CDR3 regions have the capacity to reach and
recognize cryptic and hidden conformational epitopes that are otherwise inaccessible or not
immunogenic for conventional antibodies, which makes them potent alternatives to conventional
antibodies. Furthermore, VHHs still share the recognition of planar epitopes which are usually
recognized by conventional antibodies (Muyldermans et al., 2009). A notable study by De Genst
et al. in which a precise illustration strengthened by thorough crystallographic analysis could
show the difference in epitopes recognized by conventional and VHH antibodies, they compared
the crystal structures of conventional antibodies-lysozyme complexes with those of VHHlysozyme complexes (De Genst et al., 2006b).
Collectively, in contrast to antigen-binding entities derived from classical antibodies, the
use of recombinant VHH offers numerous advantages in biotechnology and medical applications
due to some valuable intrinsic properties such as:


Smaller size allowing better penetration into dense tissues and neutralization of hidden
antigen (Wernery et al., 1999; van Vliet et al., 2002; Stijlemans et al., 2004) or tumors
(Cortez-Retamozo et al., 2004),



Higher thermo and chemical stability (Stok et al., 1999; Frenken et al., 2002),



Favorable structural features and their ability to form unique paratopes (De Genst et al.,
2006b; Wesolowski et al., 2009),



Superior specificity and affinity for the antigen due to the in vivo affinity maturation
(antigen-specific VHHs can bind to their corresponding antigens with sub-nM affinities),



There are various efficient methods of VHH generation with a high yields and selection
in a variety of expression systems (e.g. bacteria or yeasts) (de Geus et al., 2000; Harmsen
& Haad, 2007),



A stringently monomeric behavior with no sign of spontaneous dimerisation, so that
VHH samples are more homogeneous.
Finally, the compulsory nature of VHHs makes them the best candidate to develop bi-and

multi-specific antibodies or immuno-conjugates by fusing the genes of a VHH with another
VHH, an enzyme and/or a toxin in one expression unit (Conrath et al., 2001b). Recently, a
genuine method has been proposed by a group in the National Research Council of Canada, in
order to obtain penta-valent VHH molecules that could increase their apparent affinity by
introducing the avidity effect (Zhang et al., 2003).
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2.4 Induction, Isolation, Expression and Purification of Camelidae VHH
Recombinant DNA technology in addition to the vast development of various powerful selection
strategies allowed the fast and efficient cloning of the harvested pool of VHHs from an
immunized dromedary library and the selection of the antigen specific binders from this pool.
Accordingly, it became feasible to have access to single domain antigen-binding entities.
The most popular approach to select recombinant antigen-recognizing protein fragments
– i.e. VHH binders, is the modified method of the biopanning of phage display libraries. Phage
display is a technology in which genotype and phenotype of various types of bacteriophages are
physically linked via inserting the gene of interest, which expresses a protein, within the
phagemid technology for displaying it on the surface of a filamentous bacteriophage. Displaying
a protein, such as VHH fragment, on the surface of a bacteriophage enables the utilization of
these modified bacteriophages to select and enrich antigens specific binders through consecutive
panning rounds (Ghahroudi et al., 1997; Verrips et al., 2000; Brissette & Goldstein, 2007).
In an alternative strategy, Tanha et al., it was possible to generate a large single pot of
naïve VHH library, cloned from a number of healthy llamas, from which binders were retrieved
after multiple rounds of biopanning (Tanha et al., 2001). Furthermore, the framework-2 region of
a human VH was adapted with the intention of mimicking the camelidae VHH, a process known
as “camelization” (Davies & Riechmann, 1994). After that, the CDR3 codons of these camelized
VH were then randomized and cloned in a phage display phagemid to retrieve binders from this
obtained synthetic library (Davies & Riechmann, 1995). Noteworthy, the latter two strategies
have the advantage that the immunization was totally avoided, however, the selected binders are
usually of lower affinity and they need further mutagenesis steps to arrive at valuable kinetics.
Therefore, it might be more convenient to use immune libraries to arrive at antigen-specific
VHHs with appropriate characteristics for detailed applications (Tillib, 2011).
2.4.1

Induction of HCAbs

The Immunization procedures to elicit HCAbs in camelids are, in principle, similar to those in
use to raise conventional antibodies in other animals (e.g. rabbit or goat immunization). In
general, about five repetitive subcutaneous injections of antigen volume, of concentration about
50-500 µg, mixed with equal volume of Freund or Gerbu adjuvant, are carried out in the course
of 5-6 weeks. The initial immunization dose, as a rule, is using complete adjuvant and the rest of
19

booster doses use incomplete one (Conrath et al., 2001a). Worth mentioning, widely divergent
antigens can be used all together for a single immunization (Lauwereys et al., 1998; Van der
Linden et al., 2000). Likewise, subcutaneous injection of whole cells (108 cells in phosphate
buffered saline PBS per shot) and other types of adjuvant is still successfully used to raise an
HCAbs response (Maass et al., 2007). The bargain of selecting HCAbs from synthetic or naïve
libraries is well-studied, it is confirmed that the HCAbs generated from immune libraries can
recognize antigens with a higher affinity (i.e. binding affinity is from nanomolar to subnanomolar range) since they undergo in vivo affinity maturation progression (Muyldermans et
al., 2009; Ghassabeh et al., 2010). In spite of this limitation, the non-immune and synthetic
libraries are still considered as attractive alternatives in a number of cases: (i) when only limited
amount of antigen is available and/or (ii) in case of the antigen being toxic or non-immunogenic
to camelids.
2.4.2

Isolation of antigen specific VHHs

Polyclonal, mono- and bi-valent, VHH antibodies can be isolated from the inborn HCAbs using
primitive, simple and yet efficient proteolysis method. A prominent study by Lauwereys et al.
could generate polyclonal monovalent VHHs containing α-amylase-specific binders by digesting
the harvested HCAbs isotype IgG3 from Protein G chromatography with endo-Glu V8 protease.
Afterward, the binders were separated from the cleaved Fc part by running chromatography on
protein-A which is able to retain the Fc part. It is worth noting that, a considerable fraction of the
dromedary VHHs still firmly bind to protein-A, which drastically affects the applicability of this
method. In 1998, Muyldermans and his group at VUB laboratories could successfully obtain bivalent VHH (i.e. VHH2) by digesting the purified IgG3 isotype of HCAbs with pepsin, trypsin or
papain (Lauwereys et al., 1998). These protease enzymes could cleave the hinge region primarily
following the first disulfide bond linking the γ3 heavy chains, although, these methods can
generate polyclonal VHHs from HCAbs IgG3 isotype, hitherto, the generation from IgG2 isotype
is still calling for further development.
Monoclonal antigen-specific VHHs of compulsory specificity can be easily identified via
phage display method and can be produced in bacterial expression systems in relatively high
amounts compared with the conventional antigen binding fragments Fabs (Nguyen et al., 2001;
Olichon & Surrey, 2007). Isolation of VHHs includes the cloning of the full repertoire of VHH
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genes extracted from the β-lymphocytes isolated from the peripheral blood (about 100 mL of
whole blood) of immunized camel. Multiple sequential biochemical procedures are carried out:
(i) total RNA isolation from white cells of blood, lymph node or spleen, (ii) complementary
DNA (cDNA) synthesis, (iii) two-step polymerase chain reaction PCR using specific primers to
amplify VHH sequences, (iv) constructing a VHH library of a satisfactory size. The construction
of large immune libraries with the purpose of picking up the perfect antigen-specific binder has
been proven redundant, this is elucidated by the fact that VHH unlike the conventional
antibodies can bind to their target antigens by asset of only one single domain. Whereas, the
antigen binding of the conventional forms usually depends on the presence of heavy and light
chains. Accordingly, construction of conventional antibodies’ libraries should have room for all
possible random association between heavy and light chains. Hence, it is highly favored to
construct very large libraries to acquire all possible combinations of VH–VL chains, in order to
find few of them which are similar to the original pairing scheme generated in vivo (Lauwereys
et al., 1998; Alvarez-Reuda et al., 2007). Afterward, (v) the selection procedure and the
identification of specific binders from VHHs libraries is done by the enrichment via phage
display consecutive rounds of biopanning against the antigen of interest (Nguyen et al., 2001).

Figure 1.8. Schematic Illustration of Phage Display Biopanning (Schirrmann et al., 2011)
21

Recently, it was suggested by Tillib et al. to use, in parallel, both conventional helper
phage (M13KO7) and a modified helper phage which has an N-terminal deletion in the phage
surface protein gIII which would greatly improve the selection procedure (Tillib et al., 2010). Up
to date, all the available data obtained from diverse studies point out that the differential
character of the selection of particular variants of VHH sequences in the process of biopanning
procedure are independent of the number of panning rounds. Although one kind of clones can be
successfully picked just right after the first panning round, yet, it can be lost during the following
rounds. Nonetheless, other clones can be selected only after three or four panning rounds. In
conclusion, it is important to set up the right design of the selection and monitoring procedure so
as to improve the possibility of finding appropriate binders with explicit properties, such as the
higher affinity, higher solubility and/or superior expression yield (Ghahroudi et al., 1997;
Verrips et al., 2000; Tillib, 2011).
2.4.3

Expression Systems: Factors Affecting the Yield

The expression of VHHs in different expression systems has been well established, some studies
could obtain high expression yields ranging from 5-10 mg/L in E. coli baffled shake flask
cultures (Rahbarizadeh et al., 2005). Moreover, there are several reports of VHH production in
plant and animal cells, for instance, tobacco and Chinese hamster ovary cells, respectively
(Ismaili et al., 2007; Rajabi Bazl et al., 2007). VHH have also been produced in yeasts
(Thomassen et al., 2002; Rahbarizadeh et al., 2006), although, most of such VHHs are (i)
occasionally N-glycosylated (Frenken et al., 2000; Harmsen et al., 2005), which can severely
affect their antigen binding properties (Van der Vaart et al., 2006), (ii) suffering from limited
therapeutic application due to the increased immunogenicity resulting from the addition of yeastspecific high-mannose oligosaccharides, and (iii) of short serum half-life, due to the binding of
the N-glycosylated VHH to specific mannose receptors found in the reticuloendothelial system
RES (Sethuraman & Stadheim, 2006).
The production levels of VHHs in various microorganisms may vary radically among
different clones such differences depend on (i) their specific sequences, (ii) the host and (iii)
even nutrients in host growth media (Rahbarizadeh et al., 2006; Olichon et al., 2007; Van de
Laar et al., 2007). As for sequences, it seems that sequence patterns of VHHs can affect their
production level as follows: (a) production rate of conventional-like VHH is generally reduced in
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yeast (Harmsen & Haad, 2007), (b) unpaired C-terminal cysteine residues result in a decrease in
the expression level (Simmons et al., 2006), and (c) hydrophilic residues found in positions
interacting with CH1which results in high expression levels (Harmsen & Haad, 2007).
Regarding the host and nutritional media factors, VHHs’ production rate in baker’s yeast
is related to the host growth rate (Thomassen et al., 2005), in addition, it can be increased by
changing the medium (Van de Laar et al., 2007). Furthermore, supplementation of the medium
has also been reported to improve VHHs production in Pichia pastoris (Rahbarizadeh et al.,
2006). In conclusion, the lack of post-translational modifications and the limitations of the
folding machinery make the overexpression and production of conventional antibodies in
bacteria and yeast almost impossible. Whereas, VHH are active without such modifications, and
as being a single chain without the fragment crystallizable region Fc domain they are easily
expressed in bacteria and yeast (Arbabi-Ghahroudi et al., 2005). It is worth mentioning that, the
expression levels for camelid VHHs in some yeast, for instance, Saccharomyces cerevisiae have
been reported to be 100 mg/L from shaking flask and 1 g/L from a fed-batch fermentation
(Frenken et al., 2000), with scalable expression yield reaching 1.3 kg from a 15 m3 fermentation
(Thomassen et al., 2002).
2.4.4

Purification Methods

VHHs can be simply purified via various procedures. In 1999 Van der Linden et al. reported a
simple ultrafiltration of the supernatant of yeast cultures with purity of about 80-90% just by
passing through membranes with cut-off limits of 50 and 5 kDa in that order (Van der Linden et
al., 1999). In addition to the ultrafiltration, the utilization of the intrinsic characteristic of
subfamily III nanobodies® which bind to protein-A, many studies could purify nanobodies® by
simple chromatography methods, however not all properly folded antibodies bind protein-A
(Ghahroudi et al., 1997; Frenken et al., 2000).
Recently, the possibility of including a C-terminal (His)6-tag paved the way for using the
cost-effective chelating group-columns, nickel-nitrilotriacetic acid Ni-NTA products, a wellknown technique called immobilized metal affinity chromatography (IMAC), which frequently
produce nanobodies® with satisfactory purities for most applications (Lauwereys et al., 1998;
Alvarez-Reuda et al., 2007). Furthermore, an interesting study confirmed the practicability and
reproducibility of a simple straightforward one-step heat treatment process to purify
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Nanobodies® to a comparable level of purity to that obtained via IMAC; such swift and low-cost
alternative to conventional chromatography process can still conserve the natural functionality of
the produced antibodies (Olichon et al., 2007).

2.5 Applications of Single-Domain Antibodies
2.5.1

Medical applications: Emergence of Immunotherapy

About a century ago, Paul Ehrlich announced that “since normal cells and cancerous cells differ
in their staining properties, there should be a “magic bullet” to target only cancer cells”. This
presumption did not come to realization until 1975 when Köhler and Milstein introduced the first
mouse hybridoma technique (Köhler & Milstein, 1975) and, ever since, the production of
monoclonal antibodies mAbs became a fact. In reality, the constant domains within the
antibodies are not essentially involved in the antigen recognition mechanism. In view of that, a
range of smaller antibody fragments which still preserve the antigen-binding affinity have been
designed. Figure 1.9 illustrates various antibody fragments; mono- and bi-valent fragment
antigen binding Fab, F(ab′)2, fragment variable Fv, single chain fragment variable scFv and
eventually, the domain antibodies dAbs. Nevertheless, added to the technical difficulties, such
as, spontaneous aggregation and poor expression yields in heterologous systems, which
constantly face the generation of these antibody fragments from conventional antibodies; these
produced biomolecules additionally suffer from pathologically relevant immune responses. The
latter is responsible for their rapid clearance from the system and makes them unable to
effectively interact with effector functions cells (Lee et al., 1998).

Figure 1.9. Schematic Presentation of Various Antibody Fragments (Ghassabeh et al., 2010)
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In 1980, Gabrielle Boulianne and his colleagues from Toronto University and Ontario
cancer institute could design and produce the first chimeric antibodies (Boulianne et al., 1984),
which was built from a variable antibody part from murine origin fused to the constant region of
conventional human antibody. Noteworthy, after this primal experiment many attempts could
effectively reduce the human anti-mouse antibody (HAMA) immune response (Hwang & Foote,
2005). Loads of engineered designs of these murine antibodies were developed utilizing
numerous ways for the sake of resolving the antigenicity concerns, from controlling the initial
and terminal serum half lives to preventing the anti-globulin responses in order to fully exploit
their immune effector functions.
Humanization approach is the most common in which the CDRs regions are grafted into
the human IgG backbone. In addition, the resurfacing approach shows enhanced results, in which
the original human amino acids are only being replaced by the surface exposed murine residues
(Zhang et al., 2005). On the other hand, this approach suffers from a significant reduction or
complete loss of binding affinity since some of the residues in the removed framework are
critical for maintaining the CDRs’ conformation (Chothia et al., 1989; Foote & Winter, 1992).
Practically, the complex structure of full-length antibodies limits their use in only some of
medical applications, such as imaging and active targeting. Financially, the production of mAbs
also suffers from the very high costs which are increasingly becoming a burden for the
healthcare sector.
Nature has provided an inimitable answer, thanks to the exceptional repertoire of fully
functional heavy chain only antibodies of the dromedaries and llamas. All of the previously
conferred unique features of these antibody fragments imply that they will put forward
remarkable promises to be exploited as robust reagents for presenting superior therapeutic and
diagnostic applications as well as multipurpose biological properties.
2.5.2

Medical Applications: Therapeutics

Currently, there are various operational VHHs for different clinical settings, a notable study by
Baral et al. demonstrated that the generation of VHH against the sleeping sickness inducing
parasite Trypanosome rhodensiensis variance surface glycoprotein (VSG) fused to trypanolytic
factor apolipoprotein L1 (APOL1) would establish a novel generation of anti-parasitic treatment
strategies (Baral et al., 2006). In addition, toxin neutralizing VHHs have been generated against
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lethal scorpion envenoming, these venom-neutralizing antibodies could successfully provide
much higher efficacy and immunological advantages over conventional anti-venoms (Hmila et
al., 2008; Hmila et al., 2010). Moreover, Tremblay and colleagues demonstrated that the VHHs
have potential as components of therapeutic agents for reversal of botulism intoxication. The
generated VHHs could act as neuronal cell intrabody binding agents and inhibitors of
Clostridium botulinum neurotoxin proteases (Tremblay et al., 2011).
VHHs have been used as an anti-pathogens either as a direct therapeutic agent such as the
fused form used for the treatment of trypanosomiasis (Baral et al., 2006) or, indirectly, for
preventing drug degradation by the pathogen (Conrath et al., 2001a). Moreover, VHH could
reduce the morbidity of rotavirus induced diarrhea in mice (Van der Vaart et al., 2006).
Furthermore, Antagonistic anti-TNF-β nanoantibodies established an outstanding therapeutic
efficiency in a murine rheumatoid arthritis model. The therapeutic outcome was much higher
than the effect of the conventional antibodies that are already in the use for the treatment of
rheumatoid arthritis (Coppieters et al., 2006). Table 1.2 points up various selected therapeutic
applications of VHHs (i.e. sdAbs) developed from different sources including immune, nonimmune and synthetic libraries.
Table 1.2. sdAbs for Various Therapeutic Applications
Target

Source

Application

Reference

FcgRIII (CD16)

Immune Llama

Cancer immunotherapy,

(Behar et al., 2008)

Recruitment of NK cells
TNF-alpha

Immune Llama

Rheumatoid arthritis

(Coppieters et al., 2006)

HIV-1 Subtypes

Immune Llama

Anti-viral therapy

(Strokappe et al., 2012)

Methotrexate

Immune Llama

Cancer therapy

(Alvarez-Reuda et al., 2007)

Hepatocyte

Immune Llama

Molecular cancer therapy

(Vosjan et al., 2012)

growth factor
Trypanosoma

drug discovery
Immune Dromedary

evansi
Scorpion toxin

Trypanosomiasis

(Saerens et al., 2008)

diagnosis and therapy
Immune Dromedary

Neutralization

(Hmila et al., 2008; Hmila
et al., 2010)

26

2.5.3

Medical Applications: Diagnostics

In addition to therapeutics, VHHs were effectively used in developing a range of novel
diagnostic applications. Such as, accurate determination of tumor epidermal growth factor
receptor EGFR such as human epidermal growth factor receptor 2 (HER2), a tumor-associated
molecule over expressed in about 30% of breast cancer patients. The detection was possible via
imaging the radio labeled anti-HER2 VHH with 99mTc and 68Ga (Vaneycken et al., 2011; Vosjan
et al., 2011). Noteworthy, the radio-labeling of VHHs facilitates the design of innovative
biomolecules conjugates for drug discovery, immunotherapy and diagnosis of different
biomarkers – positive tumors. As well, a notable study by Behar et al. demonstrated that high
affinity sdAbs were successfully directed against nonconventional epitopes of human
carcinoembryonic antigen (CEA), these antigen-binding sites totally differ from those defined by
contemporary murine monoclonal antibodies (Behar et al., 2009).
Chromobodies are fusion proteins that comprise an antigen binding VHH and a
fluorescent protein. For instance, green fluorescent protein GFP, have been already generated
making them proficient candidates for tracking the target antigen in vivo and ex vivo. This allows
dynamic tracing and modulating the changes of target antigens at all stages of cell-cycle in living
cells using various techniques, such as, the live cell microscopy (Rothbauer et al., 2006;
Kirchhofer et al., 2010). In conclusion, such fluorescent-VHH conjugate show high potential for
further theranostic applications. For example, the tracing of the fate of a certain antigen of
interest (e.g. parasitic antigen) inside the living host, that possibly will pave the way for
discovering a novel drug based on blocking a critical stage of the parasite life cycle. Finally,
Table 1.3 points up different selected diagnostic applications of VHHs.
Table 1.3. sdAbs for Various Diagnostic Applications
Target

Source

Application

Reference

Dendritic cells

Immune Camelid

in vivo imaging

(De Groeve et al., 2010)

Taenia solium

Immune Dromedary

Cysticercosis

(Deckers et al., 2009)

Trans-sialidase

Immune Llama

Trypanosomiasis

(Ratier et al., 2008)

CEA

Immune Llama

Tumor targeting

(Behar et al., 2009)

HER2

Immune Llama

in vivo imaging

(Vaneycken et al., 2011)

hPSA

Immune Dromedary

Cancer Diagnosis

(Saerens et al., 2004)

MUC1

Immune Camelid

Tumor targeting

(Rahbarizadeh et al., 2006)
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3

Materials & Methods

3.1 Materials
3.1.1 Reagents, Buffers and Media
Table 1.4. Reagents, Buffers and media utilized in this research (Vincke et al., 2012)
Reagents, Buffers and Media Composition

Supplier

Dithiothreitol DTT

0.1 M DTT

Sigma-Aldrich

Complete Freund adjuvant 1

killed Mycobacterium tuberculosis

Sigma-Aldrich

non-metabolizable oils
Incomplete Freund adjuvant

non-metabolizable oils

Sigma-Aldrich

DiEthylPyroCarbonate

10 µL DEPC in 10 mL H2O

Sigma-Aldrich

Treated Water DEPC

incubate for 2 h at 37 ⁰C

or overnight at room temp.
autoclave
Saline solution, 0.9% NaCl

9 g/L NaCl

TRIzol reagent kit

Merck
Invitrogen

Chloroform/ Iso-amylalcohl

12 mL Chloroform

(24/1)

0.5 mL Iso-amylalcohol

Ethanol alcohol

100 % EtOH

Sigma-Aldrich
Sigma-Aldrich

QIAquick Gel Extraction kit

Qiagen

QIAquick PCR purification kit

Qiagen

Sodium acetate (pH 5.2)

3 M Sodium Acetate

Merck

adjust pH with 37% HCl
GenElute™ Plasmid Miniprep

Sigma-Aldrich

GenElute™ PCR clean-up kit

Sigma-Aldrich

LB medium (Luria-Bertani

10 g/L Tryptone

Duschefa Biochemie

medium, pH 7.0)

5 g/L Yeast extract

Duschefa Biochemie

10 g/L NaCl

Merck

adjust to 1 L Milli-Q H2O
autoclave

1

Gerbu adjuvant (LQ#3000, GERBU Biotechnik GmbH, Heidelberg, Germany) can also be used.
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Reagents, Buffers and Media Composition

Supplier

LB agar

Duschefa Biochemie

15 g/L Microagar
adjust to 1 L with Milli-Q H2O
autoclave

LB agar Amp/glucose

2xTY medium (pH 7.0)

LB agar
100 µg/mL Amp

Duschefa Biochemie

1/10 20% glucose

Duschefa Biochemie

16g/L Tryptone

Duschefa Biochemie

10 g/L Yeast extract

Duschefa Biochemie

5 g/L NaCl

Merck

adjust to 1 L with Milli-Q H2O
autoclave
2xTY Amp/Kan

TB (Terrific Broth)

2xTY medium
100 µg/mL Amp

Duschefa Biochemie

70 µg/mL Kan

Duschefa Biochemie

12 g/L Tryptone

Duschefa Biochemie

24 g/L Yeast extract

Duschefa Biochemie

2.31 g/L KH2PO4

Merck

12.54 g/L K2HPO4

Merck

4 mL/L Glycerol

Duschefa Biochemie

adjust to 1 L with Milli-Q H2O
autoclave
SOB medium

20 g Tryptone

Duschefa Biochemie

5 g Yeast extract

Duschefa Biochemie

0,5 g NaCl

Merck

1,86 g KCl

Merck

adjust to 1 L with Milli-Q H2O
autoclave
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Reagents, Buffers and Media Composition
SOC medium

Supplier

25 mL SOB
500 µL 1M MgSO4

Merck

125 µL 2M MgCl2

Merck

PBS (Phosphate Buffered

136 mM NaCl

Merck

Saline, pH 7.4)

2.6 mM KCl

Merck

10 mM Na2HPO4

Merck

1.5 mM NaH2PO4

Merck

PBS-milk

PBS + 2 % milk powder

Nestlé

PBS/Tween PBST

PBS + 0.05 % (v/v) Tween-20

Sigma-Aldrich

Tris-HCl (pH 8.0)

1 M Trizma® base

Sigma-Aldrich

adjust pH with 37% HCl
adjust to 1 L with Milli-Q H2O
TES (Tris-EDTA-sucrose) pH

0.2 M Tris-HCl (pH 8.0)

8.0

0.5 mM EDTA

Merck

0.5 M Sucrose

Duschefa Biochemie

10x TBE (Tris-borate-EDTA

108 g Trizma® base

Sigma-Aldrich

buffer)

55 g Boric acid

Merck

9.3 g EDTA

Merck

adjust to 1 L with Milli-Q H2O
PEG/NaCl solution

20 % w/v PEG-6000

Duschefa Biochemie

2.5 M NaCl

Fisher Scientific

adjust to 1 L with Milli-Q H2O
autoclave
Ampicillin (Amp 100 mg/mL

1 g Amp

Duschefa Biochemie

stock solution)

10 mL 70 % ethanol

Fisher Scientific

sterilization by filtration through

Millipore

0.22 µm Express™ Plus-filter
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Reagents, Buffers and Media Composition

Supplier

Kanamycin (Kan 70 mg/mL)

Duschefa Biochemie

0.7 g Kan
10 mL Milli-Q H2O
sterilization by filtration through

Millipore

0.22 µm Express™ Plus-filter
IPTG (Isopropyl-β-D

1 M IPTG

thiogalactopyranoside)

Milli-Q H2O

Duschefa Biochemie

sterilization by filtration through

Millipore

0.22 µm Express™ Plus-filter
DNA loading buffer

0.25 % Bromophenol blue

Merck

0.25 % Xyleen cyanol FF

Merck

15 % Ficoll™ PM400

Amersham

84.5 % Milli-Q H2O

Bioscience

Ethidium bromide (EtBr

1g EtBr

Merck

10mg/mL)

dissolve in 100 mL of Milli-Q H2O

20x MES buffer (pH 8.3)

195.2 g MES (2-(N-morpholino)
ethane sulfonic acid)
®

Sigma-Aldrich

121.2 g Trizma base

Sigma-Aldrich

6 g EDTA

Merck

20 g SDS

Duschefa Biochemie

adjust to 1 L with H2O
SDS-PAGE Staining solution

0.125 g Coomassie® Brilliant Blue

Fluka

R250
50% Methanol

Lamers & Pleuger

10% Acetic acid

Vel

adjust to 1 L with H2O
SDS-PAGE Destaining

10% Acetic acid

Vel

solution

40% Methanol

Lamers & Pleuger

adjust to 1 L with H2O
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Reagents, Buffers and Media Composition
AP-blot buffer (pH 9.8)
Trimethylamine (TEA)

Supplier

1 M Diethanolamine
1 mM MgSO4

Merck

70 µL TEA

Sigma-Aldrich

5 mL Milli-Q H2O
0.5M Imidazole in PBS

3.5 g Imidazole

Sigma-Aldrich

dissolve in 100 mL PBS
adjust pH to 7.5 with 37% HCl with

Merck

sterilization by filtration through

Millipore

0.22 µm Express™ Plus-filter
HEPES buffer (pH 7.0)

1 mM HEPES

Sigma-Aldrich

Autoclave
10X Buffer H

500 mM Tris-HCl, pH 7.5

Roche

100 mM MgCl2
10 mM Dithiothreitol (DTT)
1000 mM NaCl
10X Buffer R

3.1.2

Fermentas

Equipments and Consumables

Table 1.5. Equipments and Consumables used in this research (Vincke et al., 2012)
Equipment/Consumable

Supplier

Lab centrifuge with swing-out rotor

Eppendorf

Separation tube for whole blood lymphocytes and peripheral

Greiner Bio-One

monocellular cells Leucosep™
Falcon tubes

BD Falcon™

RNase-free tubes and Micropipette tips

Eppendorf

Pasteur glass pipette and Ball to aspirate
Water bath and heating block
Thermocycler

BioRad
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Equipment/Consumable

Supplier

Agarose gel electrophoresis

BioRad

UV trans-illuminator
Vortex
Microcentrifuge
Nanodrop® spectrophotometer

Thermo Scientific

Shaker incubator
Gene Pulser Electroporation instrument

BioRad

Electroporation cuvettes

BioRad

Cell scraper

BD Biosciences

Large square Petri dishes (243 x 243 mm)
Glass beads, average size

E&R Chemicals and

(0.25-0.35 cm diameter)

equipments

Maxisorb 96-well microtiter plate

NUNC

Round bottom 96-well microtiter plate

BD Biosciences

Microtiter plate reader
Gel-filtration column HiLoad S75 (16/60) On ÅKTA Express
®

GE Healthcare

HIS-Select Nickel Affinity Gel

Sigma-Aldrich

Vivaspin-15 (MWCO 5,000 PES)

Vivasciences-Sartorius

PD-10 columns

GE Healthcare

3.1.3

Bacterial Strain

Two bacterial Escherichia coli (E. coli) strains were used in this study:
(i)

E. coli TG1 strain for biopanning and the selection of antigen specific VHH
•

E. coli TG1:
K12, Δ(lac-pro), supE, this, hsdD5/F′traD36, proA+B+, lacq, lacZΔM15

(ii)

E. coli WK6 strain for the Nanobodies® expression, they are su- which make them
unable to read-through the amber stop codon.
•

E. coli WK6:
K12, Δ(lac-proAB) galE, StrA/F′, laclq, lacZΔM15, proA+B+
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3.1.4

Plasmids: pMECS

The pMECS is a pUC derived phagemid vector used for phage display, it is designed for
efficient production of soluble Nanobodies® and the selected VHH coding genes are cloned
between a pelB leader signal sequence, which transports the VHH to the bacterial periplasm. The
phagemid has an F1 origin of replication, upstream of a hemagglutinin tag (HA-tag), a Cterminal hexahistidine-tail (His6) and gene III from M13 bacteriophage. The pMECS vector
contains an ampiciline resistance gene as well. Figure 1.10 displays the pMECS gene map.

Figure 1.10. Schematic Representation of pMECS Vector (Florea, 2011)
The relevant genes, restriction enzymes and tagging sites are given:
•

Multiple cloning sites.

•

E coli. Plac promoter: Isopropyl-β-D-thiogalacto-pyranoside (IPTG) inducible.

•

Pectate lyase B (pelB) signal sequence: bacterial Sec-dependent translocation signal
sequence transports the unfolded protein (Nanobody®) into the periplasm.

•

Gene III (g III): encodes the phage coat protein (pIII) of phage M13. The protein of
interest (the Nanobody®) to be displayed is fussed to pIII and that will allow the VHH to
be displayed together with pIII on the phage coat for panning. An amber stop codon
(TAG) is located between the HA-tag and gIII, which is partially suppressed in a
suppressor strain such as E. coli TG1.
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•

Polyhistidine tag (His6): sequence located downstream of the VHH gene. It is used for
ease of purification on immobilized metal affinity chromatography (IMAC).

3.1.5

Bacteriophage

M13KO7 helper phage (> 1011 plaque forming units/mL), in-house prepared, is an M13
derivative filamentous bacteriophage. The native particle is a thin, cylindrical shape usually 900
nm long and 6–7 nm in diameter (Carmen & Jermutus, 2002). It carries the mutation Met40Ile in
geneII, with the origin of replication from P15A and the kanamycin (Kan) resistance gene from
Tn903 both inserted within the M13 origin of replication. M13KO7 is capable to replicate in the
absence of phagemid DNA. Figure 1.11 illustrates the schematic diagram of the M13 phage
vector. While, in the presence of a phagemid bearing a wild-type M13 of f1 origin a singlestranded phagemid is preferentially packaged and secreted into the culture medium.

Figure 1.11. Schematic Diagram of the M13K07 Phage Display Vector Used for Cloning
Libraries of Immunized Camelids. VHH are expressed on the phage coatimmunized camelids,
afterward the inserted VHHs codons are expressed on the phage coat as fusion to the gIII
protein (Wesolowski et al., 2009)
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3.1.6

Primers

Table 1.6. All used PCR primers utilized for the amplification and sequencing of the VHH genes.
Restriction enzyme sites are underlined (Arbabi-Ghahroudi et al., 1997)
Primers

Sequence (5'- 3')

A6E

GATGTGCAGCTGCAGGAGTCTGGRGGAGG

Call001(20 uM)

PstI
GTCCTGGCTGCTCTTCTACAAGG

Call002 (20 uM)

GGTACGTGCTGTTGAACTGTTCC

FP

TTCCCAGTCACGAC

RP

CACACAGGAAACAGCTATGAC

MP57

TTATGCTTCCGGCTCGTATG

GIII

CCACAGACAGCCCTCATAG

Primer38

GGACTAGTGCGGCCGCTGGAGACGGTGACCTGGGT
NotI
BstEII

3.1.7

Enzymes

Table 1.7. All used restriction enzymes utilized for the cloning of the VHH fragments. Restriction
enzyme sites are illustrated (Vincke et al., 2012)
Restriction enzymes

Cutting Site

Supplier

Eco91I (10 u/µL)

5’…G^GTNACC…3’
3’…CCANTG^G…5’

Fermentas

Xba1 (10 u/µL)

5’…C^TCGAG…3’
3’…GAGCT^C…5’

Fermentas

NotI (10 u/µL)

5’…GC^GGCCGC…3’
3’…CGCCGG^CG…5’

Roche

PstI (10 u/µL)

5’…CT GCA^G…3’
3’…GDACGTC…5’

Roche

ExoI (20 u/µL)

Catalyzes the removal of nucleotides from
single-stranded DNA in the 3' to 5' direction

Fermentas
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Table 1.8. PCR reagents, DNA polymerase and other enzymes utilized for the cloning of the
VHH fragments
PCR reagents, DNA Polymerase and other enzymes

Supplier

Oligo-dNT12-18

Invitrogen

dNTP mix (10 mM each)

Invitrogen

Superscript II First-Strand Synthesis System,

Fermentas

for Reverse Transcriptase RT-PCR(200 u/µL)
Ribolock ™ RNase Inhibitor,

Fermentas

Human Placental RNAse Inhibitor HPRI (40 u/µL)
FastStart Taq polymerase (5 u/µL)

Roche

Taq DNA polymerase

Sigma-Aldrich

T4 DNA ligase (5 u/µL)

Fermentas

Shrimp alkaline phosphatase (SAP, 1 u/µL)

Fermentas

DNA smart ladder

Eurogenetec

Hinf (10 u/µL)

Fermentas

ExoSAP-IT

Affymetrix

3.1.8

Antibodies

Table 1.9. Antibodies utilized for IgG ELISA, PE ELISA and Nanobodies® selection
Antibody

Supplier

Rabbit anti-camel polyclonal Ab

Sigma-Aldrich

Rabbit anti-VHH polyclonal Ab

Developed in house

Goat anti-rabbit IgG alkaline phosphatase conjugate

Sigma-Aldrich

Mouse anti-M13 horse radish peroxidase conjugate

Amersham Biosciences

Mouse anti-His-tag mAb

Abd Serotec

Goat anti-Mouse IgG

Amersham Biosciences

3.1.9

2

Animal and Materials used for Immunization and Nanobodies® Selection



Young adult camel (well behaved 2, three years old, 250-275 kg male).



Native Schistosoma mansoni Cathepsin-B (SmCB) Antigen, 0.5-1mg.

The behavior of Camel is considered as a general indicator of its health status (Wernery et al., 1999)
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Execratory Secretory Schistosoma mansoni (SmES) Antigen, 0.5-1 mg.

Both proteins are cooperatively provided by Dr. Ibrahim Rabee, Immunology Department,
Theodor Bilharz Research Institute TBRI, Giza, Egypt.
Noteworthy, the used antigens are preferred to be well folded/structured proteins.
Nevertheless, the proteins used for immunization can be contaminated with other neither non
proteases nor toxic antigens, however, it is highly recommended to use high purity proteins for
biopanning and binders identification (typically recombinant proteins).

3.2 Methods
In this section, a detailed step-by-step description of the entire processes of developing of the
variable domain of the heavy chain of the heavy-chain antibodies VHH, also known as singledomain anti-bodies (sdAbs) and Nanobodies® (Nbs). Part of the steps and methods will not be
fully described, those should be carried out as per their manufacturers and suppliers described.
Moreover, other parts will be described according to the Department of Molecular and Cellular
Interactions Laboratories’ (CMIM Lab), Flanders Interuniversity institute for Biotechnology
(VIB),Vrije Universiteit Brussel (VUB) in-house protocols. The extent of description will start
with a camel’s immunization step, going through the expression and purification of the enriched
antigen specific binders. Finally, brief estimation of the binding affinity properties of the
produced sdAbs will be addressed as well.
3.2.1

Camel’s Immunization

A young adult male, well behaved with normal appetite, three years old healthy camel was
carefully selected to immunize. The dromedary camel was subcutaneously immunized multiple
times with the antigens mixed with (a) Freund complete adjuvant (for first injection) and (b)
Freund incomplete adjuvant (for booster injections). The presence of adjuvant is mainly to
enhance the immune response of the animal in order to increase the titer of the B lymphocyte
cells. After proper amount and doses of immunization doses over an optimum period of time it is
highly anticipated to have an affinity-matured antigen-specific HCAbs expressed on the B cells.
The immunization protocol adapted in this work tones with the VIB in-house regular
protocol, and other previously reported standard immunization protocols of camels (Conrath et
al., 2001a).
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Procedure
1. The adjuvant was stored and handled as described by the manufacturer’s product
information guide.
2. Just before immunization, one aliquot of each -20 ⁰C frozen antigens was thawed and

mixed via vigorous vortex with an equal volume of adjuvant until a thick emulsion
was formed.

Critical Step: While using complete Freund’s adjuvant for first injection, vortex or shake
well to resuspend the Mycobacterium.
3. The emulsion was transferred to a syringe with an appropriately sized needle and
injected subcutaneously.
4. The immunization steps were designed as follow:
Table 1.10. Camel Immunization Steps
Injection

Time Interval

Adjuvant Volume

Antigen Volume (1 mg/mL)

First Injection

Day 0

250 µL

250 µL

1st Boost

One Week

250 µL

250 µL

2nd Boost

Two Weeks

200 µL

200 µL

3rd Boost

Three Weeks

150 µL

150 µL

4th Boost

Four Weeks

100 µL

100 µL

5 Boost

Five Weeks

50 µL

50 µL

6th Boost

Six Weeks

50 µL

50 µL

th

Note: The gradual tapering of the injected doses’ concentration was intended to enrich
only the B cells which express HCAbs of high affinity.
Caution: Despite the fact that camels are not commonly considered as experimental
animals, general regulations concerning to animal welfare, protection and good experimental
practices were taken into consideration. During the immunization schedule routine checkups
were carried out twice a week to insure the proper supply of nutrition for camel in order to
maintain good health, in addition, some developed local tumefactions were watchfully treated.
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3.2.2

Preparation of Peripheral Blood Lymphocytes and Extraction of Total RNA

Procedure
1. Approximately 100 mL of peripheral blood was collected four days after the last
boost on an anticoagulant EDTA (2g EDTA/100 mL blood).
2. The anti-coagulated blood was diluted with an equal volume of 0.9% NaCl.
3. Carefully, about 30 mL of diluted blood was transferred into each Leucosep™ tube.
4. The tubes were centrifuged at room temperature for 10 min at 1000 g.
Critical Step: The centrifugation must be carried out using a swing-out rotor, while both
acceleration and deceleration breaks were disabled.
5. The plasma layer formed in the topmost was carefully removed via Pasteur pipette as
much as possible in order to minimize the contamination of the underneath peripheral
blood lymphocytes PBLs and transferred to another tubes for further IgGs
purification and for evaluation of immune response against antigens.
6. All the procedures followed the recommended experimental practice of the
manufacturer’s instruction manual, as illustrated in Figure 1.12-1.15.

Figure 1.12. Filling with diluted blood before centrifugation. The anti-coagulated and diluted
whole blood samples were carefully transferred to each Leucosep™ tube.
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Figure 1.13. Layers Separation after Centrifugation. After centrifugation the sequence of layers
occurs as follows (a) plasma; (b) enriched cell fraction (white ring interphase of lymphocytes
and PBMC’s); (c) separation medium; (d) porous frit barrier; (e) separation medium, and
finally (f) pellet (erythrocytes and granulocytes).

Figure 1.14. Harvest PBLs and

Figure 1.15. Transferring plasma to

PBMCs by means of a Pasteur pipette.

other tubes for further experiments.

Caution: All blood samples must be handled with care in accordance with the policies
and procedures of working facility. In case of any accidental exposure or contamination with
blood an appropriate medical treatment must be instantly initiated.
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7. The collected PBLs volume was divided into two fresh centrifuge tubes, afterward
they were diluted and washed twice with at least 10 times volume of phosphate
buffered solution PBS and the tubes were centrifuged at 4 ⁰C for 10 min at 250 g.

8. The supernatants were decanted, each cell pellet was gently re-suspended in about 5
mL PBS, all the suspension were collected in one tube, afterward, the PBLs washed
two more times via centrifugation as described above (see Method 3.2.2.7).
9.

Total RNA was isolated from the prepared PBLs using TRIzol reagent kit, where all
the procedures followed the technical instruction manual of supplier.

10. The RNA concentration was measured by UV-spectrophotometer (i.e. OD260nm of 1
approximately corresponds to 40 µg RNA/mL).
Pause Point: The isolated RNA can be used immediately to synthesize the first
complementary DNA strand (cDNA) or can be stored at -80 ⁰C.
3.2.3 Preparation of First Strand cDNA from RNA
Under appropriate sterilization conditions, RNAse free materials and laminar air flow, the
extracted total RNA is used as a template to prepare cDNA using commercial reagent

s.

Procedure
1. The secondary structure of the RNA was destabilized by incubating the following
mixture for 10 min at 70 ⁰C:


Total RNA

10 µL (≈ 40 µg)



Oligo-dT12-18 primer

11 µL (5.5 µg)



DEPC-H2O

105.5 µL



Total volume

126.5 µL (premix for 5 tubes x 23 µL)

2. The mixture was placed immediately on ice for 5 min, then added to it the following
mixture:


5x 1st strand buffer

44 µL



0.1 M DTT

22 µL



dNTPs (10 mM each)

11 µL



HPRI (40 units/µL)

5.5 µL



Superscript™ II Reverse Transcriptase (200 units/µL)

11 µL



Total volume

93.5 µL
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3. In a spinning rotor the mixture was well-mixed and gently centrifuged, the volume
was divided over 5 tubes (17 µL each) then incubate the mixture as follows:


42 ⁰C

for

1h

for

20 min (cDNA synthesis)

70 ⁰C

for

15 min (to inactivate the reverse transcriptase enzyme)



45 ⁰C



End cycle:



(annealing time)

4 ⁰C

Pause Point: After the incubation sequence, all the mixture tubes are collected and either
stored at -20 ⁰C or, straight away, used to amplify the VHH sequences.
3.2.4 Nested Polymerase Chain Reaction for VHH Sequences’ Amplification
The amplification if the VHH sequences’ was carried out through two consequent PCR runs. The
first run will yield two distinctive groups of amplicons: group-1, molecular weight 0.7 kb and
group-2, molecular weight 0.9 kb. The first group originated from the HCAbs-encoding mRNA
(i.e. VHH-hinge-CH2), while, the heavier second group represents the VH-CH1-hinge-CH2. The
0.7 kb fragment is purified from the agarose gel and used as a template for a nested PCR
amplification process specific to VHH-only sequences. Corresponding restriction enzymes are
introduced for further cloning into the phage display vector (pMECS, see Figure 1.10).
Procedure
1. Premix volume for about 24 tubes was prepared as follows:


H2O

954 µL



10x PCR buffer

120 µL



dNTPs (10 mM each)

24 µL



20 µM call 01 primer

24 µL



20 µM call 02 primer

24 µL



Fast Start Taq DNA Polymerase



Total volume

6 µL
1152 µL

2. The above mixture was divided over 24 tubes from Westburg strips (48 µL/tube), and
the cDNA template was added as follows:


Set 0: 2 tubes, each tube 0.5 µL of 2-fold diluted cDNA



Set 1: 4 tubes, each tube 1.0 µL of 2-fold diluted cDNA



Set 2: 4 tubes, each tube 2.0 µL of 2-fold diluted cDNA
43



Set 3: 4 tubes, each tube 2.0 µL of non-diluted cDNA



Set 4: 4 tubes, each tube 3.0 µL of non-diluted cDNA



Set 5: 5 tubes, each tube 4.0 µL of non-diluted cDNA



Negative control: no template added, only 48 µL premix

3. PCR runs was executed as per the following design:


Lid temperature:



Pre-cycle:



Thirty one cycle as follows:
•
•
•

105 ⁰C

95 ⁰C for 7 min (to activate the polymerase)

94 ⁰C

for

1 min (denaturation)

for

1 min (annealing)

72 ⁰C

for

1 min (extension)

55 ⁰C



Post-cycle:



End cycle:

72 ⁰C for 10 min (final extension)
4 ⁰C

4. The PCR products of each set were pooled, then 8 µL of each set was applied on a
1% (w/v) agarose gel in TBE buffer and EtBr. In addition, 5 µL of DNA smart ladder
was used in an adjacent lane.
5. After running the gel at 125 V for 35 min, the DNA bands were visualized under a
UV trans-illuminator, where 2-3 fragments are expected, one bigger VH fragment
(about 900-1000 bp), and 1-2 shorter bands (≈ 700 bp) for VHH.
6. All the sets in which bands around 700 bp were present and their related PCR tubes
were pooled together, then all of the pooled volume was applied on a mini-gel cast
with one wide slot of 1% (w/v) agarose gel and the gel was run ( see above).
Pause Point: the pooled 1st PCR products can be stored at -20 ⁰C.

7. After electrophoresis, the agarose gel was put on a well-cleaned UV trans-illuminator
for cutting out the specific PCR band (≈ 700 bp) with a sterile blade.
Critical Step: the exposure time to UV must be minimized as much as possible to prevent
DNA damage (e.g. pyrimidine dimer formation) that inhibits further PCR amplification.
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8. The extracted fragment was weighed then purified from the gel block using the
QIAquick Gel Extraction kit. Finally, the purified DNA was eluted in 100 µL H2O,
and its concentration was measured at OD260nm using Nanodrop spectrophotometer.
Pause Point: the eluted DNA products can be stored at -20 ⁰C, or immediately used as
template for the subsequent step (i.e. nested PCR).

9. The second step of the nested PCR was carried out by preparing a premix volume
sufficient for 10 PCR tubes, as follows:


DEPC water

358 µL



10x PCR buffer



dNTPs (10 mM each)

9 µL



20 µM VHHBACK primer

9 µL



20 µM PMCF primer

9 µL



Fast Start Taq DNA Polymerase

2.25 µL



Total volume

432 µL

45 µL

10. The premix volume kept on ice while dividing equally onto the Westburg strips tubes
(≈ 40 µL each), after that, the cDNA template was added as follows:


Set 1: 2 tubes, each tube 1.0 µL of 1st PCR purified DNA



Set 2: 2 tubes, each tube 2.0 µL of 1st PCR purified DNA



Set 3: 3 tubes, each tube 3.0 µL of 1st PCR purified DNA



Negative control: no template added

11. PCR runs was executed as per the following design:


Lid temperature:



Pre-cycle:



Seventeen cycle as follows:
•
•
•

105 ⁰C

95 ⁰C for 7 min (to activate the polymerase)

94 ⁰C

for

1 min (denaturation)

for

1 min (annealing)

72 ⁰C

for

1 min (extension)

55 ⁰C



Post-cycle:



End cycle:

72 ⁰C for 10 min (final extension)
4 ⁰C

12. From each set, 8 µL was applied on a 1% (w/v) agarose gel in TBE buffer and EtBr.
In addition, 5 µL of DNA smart ladder was used in an adjacent lane.
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13. After running the gel at 125 V for 35 min, the DNA bands are visualized under a UV
trans-illuminator, where the presence of 400 bp bands are anticipated, which
represents the size of VHHs.
14. All successful PCR sets are pooled together, and the amplified DNA was purified
using QIAquick PCR purification kit. Finally the purified DNA was eluted in about
200 µL H2O and the concentration was measured at OD260nm using Nanodrop
spectrophotometer.
Pause Point: the 2nd PCR eluted DNA products can be stored at -20 ⁰C, or immediately

used for the subsequent steps.

3.2.5 Digestion of VHHs and pMECS and Ligating Same
Procedure
1. The 2nd PCR product was digested overnight at 37 ⁰C, as follows:


H2O

250 µL



2nd PCR product (≈ 10 µg)

200 µL



10x H buffer



PstI (40 units/µL)

5 µL



NotI (40 units/µL)

5 µL



Total volume

50 µL

510 µL

2. In parallel, the pMECS vector was digested overnight at 37 ⁰C, as follows:


H2O

680 µL



pMECS vector (≈ 500 ng/µL)

120 µL



10x H buffer



PstI (40 units/µL)

9 µL



NotI (40 units/µL)

9 µL



Total volume

90 µL

900 µL

3. The restriction enzyme digested 2nd PCR product was purified with QIAquick PCR
purification kit protocol, using 3 columns. Finally, the purified VHHs’ DNA was
eluted in 180 µL H2O.
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4. The eluted DNA is digested again overnight at 37 ⁰C, as follows:

Digested PCR product

176 µL



10x H buffer

20 µL



PstI (40 units/µL)

2 µL



NotI (40 units/µL)

2 µL



Total volume

200 µL

5. The restriction enzyme digested pMECS vector was purified with QIAquick PCR
purification kit protocol, using 6 columns. Finally, the purified digested vector was
eluted in 540 µL H2O.
6. The eluted pMECS vector is digested again overnight at 37 ⁰C, as follows:

Digested pMECS vector
538 µL


10x H buffer

60 µL



PstI (40 units/µL)

2 µL



NotI (40 units/µL)

2 µL



Total volume

600 µL

7. Again, the restriction enzyme digested 2nd PCR product was purified with QIAquick
PCR purification kit protocol, using 2 columns. Finally, the purified VHHs’ DNA
was eluted in 100 µL H2O and the concentration was measured at 260 nm using
Nanodrop spectrophotometer. Finally, stored at -20 ⁰C.

8. Then, 2 µL of XbaI (40 units/µL) was added to the pMECS secondary digestion
mixture and incubated for 1 hour at 37 ⁰C. The restriction enzyme digested pMECS
vector was then purified with QIAquick PCR purification kit protocol, using 4
columns, where the purified vector was eluted in 300 µL H2O (75 µL H2O each), the
concentration was measured at 260 nm using Nanodrop spectrophotometer. Finally,
stored at -20 ⁰C.

Critical Step: Some DNA molecules are only cleaved by single enzyme, the
additional XbaI digestion step for the vector will prevent the self ligation of these
molecules.
Check Point: In order to check the digestion efficiency, 0.5 and 1.0 µL of both 2nd
PCR product and pMECS vector were applied on a 1% agarose gel in TBE and EtBr
and run at 125 V for 30 min.
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9. Three different concentrations of the pMECS vector and insert were prepared in order
to get the optimal ratio, as follows:
Tube 1

Tube 2

Tube 3

pMECS Vector

4.4 µg

4.4 µg

4.4 µg

Insert – 2nd PCR

1.7 µg

3.4 µg

5.1 µg

10. To each of the above tubes, 2.5 µL T4 DNA ligase (5 units/µL) and 15 µL 10x
ligation buffer were added, then the final volume was brought up to 150 µL with
H2O, the mixture was gently mixed and span in microcentrifuge, and incubated at 16
⁰C for 4 hours.

11. After incubation, 25 µL of the following mixture was added to each tube as follows:


H2O

xx µL



10x ligation buffer

8.5 µL



pMECS (4.4 µg)

xx µL



Insert - 2nd PCR (8.4 µg)

xx µL



T4 DNA ligase (5 units/µL)



Total volume

3 µL
85 µL

Caution: The (xx) volume of the vector and the insert were carefully calculated in order
to give a final concentration of about 4.4 µg and 8.4 µg respectively. The final volume
was adjusted with H2O.
12. The mixture was gently mixed and span in microcentrifuge, and incubated overnight
at 16 ⁰C.

13. Cleaning the ligation reaction was done as follows:
13.1. The ligation reaction was heated for at 65 ⁰C for 10 min, so as to inactivate the
ligase enzyme.

13.2. All the three tubes were pooled, and then added 100 µL of H2O to a final
volume of about 610 µL.
13.3. An equal volume of TE-saturated phenol (i.e. ≈ 610 µL from the lower phase)
was added, vortex and centrifuged at 18,000 g for 10 min to separate the phases.
13.4. The upper aqueous phase was transferred to a fresh eppendorf tube, then an
equal volume of Chloroform/Isoamyl alcohol (24/1 ratio) was added, vortex and
centrifuged at 18,000 g for 10 min to separate the phases.
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13.5. Again, the upper aqueous phase was transferred to a fresh eppendorf tube, then
added 1/10th volume of 3 M sodium acetate (pH 5.2), mixed via in/out pipetting.
13.6. Added three volumes of absolute ethanol (100% EtOH), then mixed via
inverting the tubes, and then incubated at -80 ⁰C for 30 min.

13.7. The content was centrifuged at 18,000 g for 20 min, the upper liquid was
carefully removed without disturbing the “invisible” DNA pellets.
13.8. The pellet was air dried, and dissolved in 150 µL H2O and divided into two
tubes (75 µL each), the concentration was measured at OD260nm using Nanodrop
spectrophotometer and stored at -20 ⁰C.
3.2.6 Preparation of Electrocompetent E. coli TG1 Cells
Since the main objective is to obtain as large and diverse VHHs library as possible,
electroporation was performed to make the cells more receptive for vector. All the procedures of
preparing the electrocompetent cells were carried out in the cold room at 4 ⁰C.

Procedure

1. Buffers (i.e. 1 mM Hepes, pH 7.0) and 10% glycerol were freshly prepared,
autoclaved and kept at 4 ⁰C.

2. A single colony of fresh cells of E. coli TG1 was used to inoculate 5 mL 2xTY
medium in 50 mL Falcon tube, then incubated overnight at 250 rpm and 37 ⁰C.

3. About 2 mL of the overnight E. coli culture used to inoculate 300 mL 2xTY medium
in a baffled flask. Then shacked for about 3-4 h at 250 rpm at 37 ⁰C until the OD600nm
was between 0.8-1.0.

4. Once the desired OD600nm value was reached, the flask was put on ice for 1 h inside
the cold room.
5. The TG1 culture was divided over 6 ice-cooled Falcon tubes, and then centrifuged at
2,200 g for 7 min at 4 ⁰C.

6. The supernatant was carefully decanted and gently resuspended the cells in a volume
of ice-cooled 1 mM Hepes buffer (pH 7.0) equivalent to the original culture-volume.
Caution: All the resuspension steps must be carried out very gently (e.g. pipetting up and
down very slowly or swirling).
7. The suspension was centrifuged at 2,200 g for 6 min at 4 ⁰C.
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8. The supernatant was carefully decanted and gently resuspended the cells in a volume
of ice-cooled 10% glycerol equivalent to the half of the original culture-volume. Then
centrifuged at 2,200 g for 6 min at 4 ⁰C.

9. The supernatant was carefully decanted and gently resuspended the cells in 10 mL of
ice-cooled 10% glycerol and all the tubes were pooled together. Then centrifuged at
2,200 g for 5 min at 4 ⁰C.

10. Finally, the supernatant was carefully decanted and gently resuspended the cells in
ice-cooled 10% glycerol to a final volume of 1 mL.
Critical Step: It is highly preferred to use the TG1 cells immediately for transformation.
Since storage may significantly reduce their transformation efficiency.
3.2.7 Construction of VHHs Library in Phage Display Vector
The recently prepared E. coli TG1 electrocompetent cells were immediately transformed with the
previously ligation mixture stored at -20 ⁰C, and then plated on selective medium in order to
generate a minimum VHHs library size of about 107 transformants.
Procedure
1. The electroporation apparatus was set at 1.8 kV and about 20 electroporation cuvettes
were kept on ice.
2. About 50 µL of the electrocompetent cells was placed in the first electroporation
cuvette as a control, and then applied the electric shock. The vulnerable cells were
immediately treated with 400 µL SOC medium to recover.
3. The cuvette was rinsed few times by slow in and out pipetting, another 400 µL SOC
added to rinse the cuvette once more.
4. About 75 µL ligation mixture was added to the rest of the competent cells, mixed by
swirling and kept on ice for 1 min.
5. The total volume was used as follows:


Mixture (competent cells + ligation product)

65 µL



First rinse (SOC medium)

400 µL



Second rinse (SOC medium)

400 µL



All the used volume was collected in one 15 mL Falcon tube.
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6. The negative control and the transformed mixture were incubated at 200 rpm for at
least 1 h at 37 ⁰C.

7. After incubation, a serial dilution was made as follows:


Dilution – 1: 900 µL SOC + 100 µL transformed cells



Dilution – 2: 900 µL SOC + 100 µL dilution – 1



Dilution – 3: 900 µL SOC + 100 µL dilution – 2



Dilution – 4: 900 µL SOC + 100 µL dilution – 3

8. About 100 µL of dilution 3 and 4 was placed on a (90 mm) LB/Amp-Glu (i.e. 100
µg/mL Ampicillin and 2% (w/v) Glucose) small round agar plates, glass beads were
used to distribute the cells over the agar surface. Finally, plates were inverted and
incubated at 37 ⁰C for overnight.

9. The rest of the competent cells suspension was used to plate about 2 mL/plate all the
6 large square LB/Amp-Glu agar plates (243 x 243 mm). Glass beads were used to
distribute the cells over the agar surface. Finally, plates were inverted and incubated
at 37 ⁰C for overnight, these were used to calculate the transformation efficiency.

10. After incubation, the library size was calculated from the number of colonies on the
small agar plates as follows:


No. of colonies on each plate x 10 x Dilution factor x Volume

of

transformed cells = CFU/mL
11. The colonies were scrapped from the large square agar plates using 3 mL LB
medium/plate with the aid of sterile cell scraper. The scrapped cells were transferred
to a 50 mL Falcon tube. Furthermore, each plate was rinsed with 2 mL LB medium
and transferred to the tubes. Finally, the cells were pelleted down via centrifugation at
2,200 g for 10 min.
12. The supernatant was carefully decanted and the cells resuspended in LB medium to a
final volume of about 20 mL. Then 5 mL of 100 % glycerol was added, afterward, 20
small 1 mL aliquots in eppendorf tubes were prepared, one of the aliquots was diluted
100 times in 2 x TY medium, then measured the OD600nm to estimate the total number
of cells within the scraped library (where: OD600nm of 1 corresponds to about 8x108
bacterial cell/mL). Finally, all the aliquots and the falcon tubes stored at -80 ⁰C.
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Critical Step: Calculating the library amplification factor (total number of colonies
scraped divided by the total number if cells in the small aliquots) will help in estimating
the number of presented copies of each individual transformant in the library.
13. Colony PCR was carried out to determine the percentage of colonies from the library
which harbors the vector with the right insert size, premix volume for 32 tubes was
prepared as follows:


H2O

676 µL



10x PCR buffer



dNTPs (10 mM each)

8 µL



MP57 primer (20 µM)

16 µL



GIII primer (20 µM)

16 µL



FastStart Taq polymerase(5 units/µL)



Total volume

80 µL

4 µL
800 µL

14. In each PCR tube (31 tubes) 24 µL was transferred, and to each tube a single colony
from the dilution plates (i.e. 103 or 104) was added with the aid of a sterile
micropipette tips. The last 32nd tube kept as negative control.
15. PCR runs was executed as per the following design:


Lid temperature:



Pre-cycle:



Twenty eight cycle as follows:
•
•
•

105 ⁰C

95 ⁰C for 6 min (to activate the polymerase)

94 ⁰C

for

45 sec (denaturation)

for

45 sec (annealing)

72 ⁰C

for

45 sec (extension)

55 ⁰C



Post-cycle:



End cycle:

72 ⁰C for 10 min (final extension)
4 ⁰C

16. About 8 µL of each Westburg tube was applied, for electrophoretic analysis, on a 1%
(w/v) agarose gel in TBE buffer and EtBr. In addition, 5 µL of DNA smart ladder was
used in an adjacent lane.
17. After running the gel at 125 V for 35 min, the DNA bands are visualized under a UV
trans-illuminator to find out the number of colonies with the right size (i.e. 700 bp)

52

out of the 31 lanes. Whereas, the molecular weight of the vector with no insert is
about 300 bp. A satisfactory result should be at least 70%.
3.2.8 Screening and Isolation of Nanobodies®: Phage Display and Biopanning
After infecting the E. coli TG1 cells with M13K07 helper phage we could generate the library of
phages which display VHHs on their tips. The presence of the amber stop codon (TAG) between
the VHHs sequences and the M13K07 gene III allowed the generation of a fraction of virions
which display the VHHs on their outer tips. These virions are used for a series of consecutive
rounds of biopanning against the two antigens used in the research work (i.e. SmCB and SmES).
The enriched phages are then used to infect E. coli cells for (a) further virions’ amplification for
the next biopanning round and (b) obtaining single individual colonies of bacteria which would
be used for screening antigen-specific VHHs via ELISA.
Procedure
1. In the first day, for each antigen, one well of a flat-bottom ELISA plate was coated
with 100 µL of antigen solution at a concentration 100 µg/mL in 100 mM NaHCO3
(i.e. 100 µg/well), the plate covered with Parafilm and kept overnight at 4 ⁰C.

2. About 1 mL aliquot of the prepared library brought to room temperature and a
volume contains number of cells 10-1000 times more than the number of the library
size (i.e. the number of independent transformants) was used to inoculate 100 mL
2xTY/Amp-Glu medium (the glucose will prevent the leaky expression of VHH-M13
gene III fused protein from Plac promoter), then incubated at 200 rpm at 37 ⁰C for

about 2.5 h until OD600nm value equal 0.4-0.6 (i.e. the beginning of the exponential
growth phase), where, OD600nm of 1 corresponds to ≈ 8x108 cells/mL.

Critical Step: The number of the used cells must be at least 10 times higher than the
library size to ensure that each independent transformant is represented and will have the chance
to be tested against the antigens while performing the biopanning.
3. Then M13K07 helper phage was added at a multiplicity of infection (MOI) of about
5-20 to infect the TG1 cells, the culture medium was incubated at room temperature
for 30 min without shaking.
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Caution: The shaking of the culture after adding the helper phage may dramatically
reduce the infection susceptibility of E. coli cells due to the break off the F-Pilli which is
essential for phage infection.
4. The culture volume was divided over two Falcon tubes 50 mL, and centrifuged for 10
min at 1,500 g, then the supernatant was carefully decanted in sodium hypochlorite.
5. The infected TG1 cells pellet was resuspended in 1 mL 2xTY/Amp-Kan medium, and
then transferred to 150 mL 2xTY/Amp-Kan medium in a baffled shake flask, then
incubated overnight shacked at 225 rpm and 37 ⁰C.

6. In the beginning of the next day, a single colony of fresh cultured TG1 cells was used
to inoculate 10 mL LB medium in Falcon tube 50 mL, then incubated at 37 ⁰C and
150 rpm for 2-3 h (until it is cloudy turbid) , these cells are used to amplify the eluted
enriched phages later on.

7. The overnight 150 mL 2xTY/Amp-Kan culture was centrifuged for 30 min at 2,200 g
at 4 ⁰C. The supernatant containing the phage particles was carefully transferred

(without disturbing the TG1 pellets) equally to 4 Falcon tubes 50 mL, then 1/5th
volume of PEG/NaCl solution was added to each falcon tube, mixed well by inverting
and placed on ice for at least 30 min.
8. After incubation on ice, the tubes were centrifuged for 30 min at 4 ⁰C and 2,200 g.

the supernatant is carefully decanted in sodium hypochlorite, and the tubes were air-

dried via inverting on a tissue paper under laminar flow hood.
9. The phage pellets were gently resuspended in PBS (ensure homogenous phage
suspension and avoid foaming) to a final volume of 1 mL. Then centrifuged for 2 min
at 15,000 g in order to precipitate any existing bacterial cells, cell rubble and phage
aggregates. The concentration was measure at OD260nm after 50 to 100 fold dilutions
was done, followed by adjusting the final concentration to working concentration of
about 2 x 1012/mL in PBS, where, OD600nm of 1 corresponds to ≈ 3x1010 particles/mL.
10. The overnight-coated ELISA plate is rinsed well 5x with PBST, then 200 µL of
blocking milk 2% in PBS was added to the positive well and the non-adjacent
negative control well as well in order to block the binding sites of the residual protein.
Afterward, incubated at room temperature for 2 h. After incubation the ELISA wells
were rinsed at least 5 x with 200 µL PBST.
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11. An equal volume of phage particles (2 x 1011 particles/mL) and 2% blocking fresh
skimmed milk were mixed together (i.e. 100 µL each), then added 100 µL of the
mixture to both the positive and control wells. The plate was incubated at room
temperature for at least 1 h.
Critical Step: It is preferred to dilute the phage particles in the same blocking buffer to
minimize the background and non specific binding between VHH and the buffer
components.
12. After incubation, the phage solution was carefully decanted in sodium hypochlorite
and subsequently rinsed 10x with PBST.
13. The bound phages were eluted from the wells by adding 100 µL of freshly prepared
100 mM TEA solution (pH 11.5), and incubated same at room temperature for 10
min. The eluted phages are neutralized via transferring them to an equal volume (100
µL) of 1 M Tris-HCl buffer (pH 7.4).
Pause Point: The neutralized solution can be stored at -80 ⁰C for further procedures.
Also, 10 µL of the positive well is stored at -80 ⁰C as a backup.

14. A serial dilution, 10-folds, was prepared by mixing 10 µL of eluted virions with 90
µL of PBS buffer (the dilution range from 10-1 to 10-7) in a round-bottom ELISA

plate.
15. In a new round bottom microtiter plate, 10 µL of each phage dilution was mixed
separately with 90 µL of exponentially growing E. coli TG1 cells (from Method
3.2.8.6), then incubated without shaking for 30 min at 37 ⁰C.

16. Using a multichannel pipette 10 µL of each dilution was streaked on a small square
agar plate LB/Amp-Glu. The plate is divided into two sides (i.e. positive sample and
negative control), then the plates were air-dried under laminar flow hood for a few
minutes, finally, the plates are inverted and incubated overnight at 37 ⁰C.

17. The next day, the estimation of the enrichments was carried out by observing the
number of the grown colonies on the square plates, the bacterial growth at each side
was compared to the relative dilution of the negative control side.
18. In parallel, 50 µL of the remaining 90 µL of E. coli TG1 cells of dilution 10-3-10-5
from the positive coated wells was added to small round agar plates LB/Amp-Glu,
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then incubated overnight at 37 ⁰C. The next day all the plates are stored at 4 ⁰C for
further procedures.

19. The remaining≈ 180 µL of the neutralized eluted phages (i.e. from positive and
control) was added to about 2 mL of the exponentially growing E. coli TG1 cells

(from Method 3.2.8.6) and gently mixed, then incubated at 37 ⁰C for 30 min without
shaking, after incubation, additional 8 mL of 2xTY/Amp-Glu medium was added and
the mixture incubated at 37 ⁰C with shaking at 200 rpm for 45 min.

20. The incubated infected cells were super-infected with about 107-109 M13K07 fresh
phage particles, gently mixed, then incubated without shaking at room temperature
for 30 min. After incubation, the cells were pelletized via centrifugation at 800 g for
10 min.
21. The supernatant was carefully decanted in sodium hypochlorite, and the pellet was
resuspended in 1 mL 2xTY/Amp-Kan medium then transferred to 150 mL of the
same medium in a baffled flask. Finally, the medium was incubated overnight with
shaking at 225 rpm and 37 ⁰C.

22. By the end of the day, another flat-bottom microtiter plate was prepared as explain
above (from Method 3.8.2.1) for the consecutive biopanning rounds onward.

Critical Step: All the available data obtained from different studies indicate the degree of
difference of the selection of VHH sequences’ variants in the screening process of
biopanning procedure, in which one kind of Nanobodies® can be successfully selected
after the first biopanning round, though, it can be lost during the subsequent rounds. In
contrast, other clones can be successfully picked only after the third or the fourth round.
It is crucial to setup the appropriate design of the selection and screening procedures with
the intention of improving the possibility to come across proper VHHs with particular
properties.
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3.2.9 Identification of Phages with Antigen-Specific VHHs Binders: Enrichment Phage
ELISA and Periplasmic Extract ELISA (PE–ELISA)
If the selective enrichment was not noticed while performing the consecutive biopanning rounds,
enrichment phage ELISA offers an alternative method which is more precise. Nevertheless, if the
enrichment was still insignificantly observed, then, random single colonies from the E. coli TG1
cells infected with antigen-eluted phages are grown and their periplasmic extracts are screened
against the antigen of interest through conventional ELISA procedures. The ELISA-positive
colonies are further screened for their redundancy by colony PCR, Hinf-digestion on single
colony and DNA sequencing.
Procedure
1. Flat-bottom microtiter plate wells were coated with 100 µL of both antigens (i.e.
SmCB and SmSE) at concentration of 1 µg antigen/mL in 100 mM NaHCO3 coating
buffer in correspondence to the phage library and all the performed biopanning
rounds, the plate was covered with Parafilm and incubated overnight at 4 ⁰C.

2. After incubation, the antigen solutions were removed and rinsed 5x with PBST,
afterward, 200 µL of 2% fresh skimmed milk in PBS was added to all wells (antigen
coated and negative control), the plate was incubated at room temperature for 2 h.
3. The blocking buffer was removed and the wells rinsed 5x with PBST.
4. A mixture of 100 µL 2% fresh skimmed milk in PBS and equal volume of phage
library and amplified phages from each panning round at concentration 2 x 1010
virions was prepared, then 100 µL of the mixture used to coat all the wells. Finally,
the plate was incubated in room temperature for 1 h.
5. The coating solutions were removed and the wells rinsed 10x with PBST, then added
100 µL of 1/2000 dilution of anti-M13-HRP monoclonal antibody conjugate. Then,
the plate kept in room temperature for 1 h.
6. The antibody solutions were removed and the wells rinsed 5x with PBST, then added
100 µL of HRP substrate solution. The plate was kept in dark and the absorbance was
read at 405 nm after 10 min to 30 min with 5 min time step using a microtiter plate
reader.
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Pause Point: If no enrichment was not observed (i.e. at least 2 folds signal strength
difference between the consecutive panning rounds onwards), the random selection of
single colonies still a valid approach to be examined.
7. At least 48 single colonies from the panning round which previously showed a
relative enrichment for antigen-specific phages were picked and inoculated a 24-well
flat-bottom tissue culture plates, each well was previously filled with 1 mL TB
medium containing 100 µg/mL of ampicillin. Concurrently, each picked colony was
used to streak a reference master agar plat LB/Amp-Glu. These plates incubated
overnight at 37 ⁰C, and afterward, kept at 4 ⁰C for further procedures.

Critical Step: Each streak must be accurately numbered according to the corresponding
well of the 24-well flat-bottom tissue culture plates
8. The inoculated 24-well plates were incubated with shaking at 250 rpm, 37 ⁰C for 5-6
h (the growth progress can be observed visually), then added 10 µL of 100 mM IPTG
for a final concentration 1 mM. Then, incubated overnight with shaking at 250 rpm
and 37 ⁰C.

9. In parallel, a flat-bottom 96-well ELISA plate was coated with 100 µL antigens in
100 mM NaHCO3 at a final concentration of 1 µg antigen/well. The plate was
covered with Parafilm and kept overnight at 4 ⁰C.

10. The next day, the antigen solutions removed and the wells rinsed 5x with PBST, then,
the wells coated with 200 µL of 2% fresh skimmed milk in PBS.
11. In a swing-out rotor centrifuge the induced 24-well plates were centrifuged for 15
min at 4 ⁰C and 2,200 g. The supernatant was carefully decanted without disturbing
the bacterial cells, and then resuspended the pellets in 200 µL TES buffer. The plates
kept at 4 ⁰C for 30 min with shaking at 150 rpm.

12. After incubation, 300 µL of 1/4th dilution TES was added to each well, to causing an
osmotic shock and extract the Nanobodies® from the periplasm. The plates incubated
with shaking at 150 rpm and 4 ⁰C for 30 min. Finally, the cells pelletized via
centrifugation for 15 min at 4 ⁰C and 2,200 g.

13. During the centrifugation, the blocking buffer in the 96-well ELISA plates was
removed and the rinsed the wells 5x with PBST.

58

14. The supernatant (i.e. periplasmic extract) from the centrifuged 24-well plates (100
µL) was transferred to the corresponding positive and negative wells on the 96-well
ELISA plates. The plates were incubated at room temperature for 1 h.
15. After incubation, the wells rinsed 5x with PBST, then added 100 µL of 1/1000
dilution of mouse anti-His tag antibody in PBS, incubated at room temperature for 1
h.
16. The antibody solution removed and the wells rinsed 5x with PBST, then added 100
µL of 1/2000 dilution of anti-mouse alkaline phosphatase conjugate, incubated at
room temperature for 1 h.
17. Finally, the enzyme solutions removed and the wells rinsed 5x with PBST, then
added 100 µL of freshly prepared alkaline phosphatase enzyme substrate, the plates
kept in dark for 10 min and read the absorbance at 405 nm to 20 min with 5 min step.
18. For the same periplasmic extract, the colony was considered positive only if the
absorbance in the antigen-coated well was at least twofold that of the non-coated
negative control well.
19. Each positive clone was digested by Hinf restriction enzyme in order to make groups
of binders with probable identical sequences.
20. Colony PCR was done, a premix volume for each sample of positive clone was
prepared as follows:


H2O

84 µL



10x PCR buffer

10 µL



dNTPs (10 mM each)

1 µL



MP57 primer (20 µM)

2 µL



GIII primer (20 µM)

2 µL



FastStart Taq polymerase(5 units/µL)



Total volume

0.3 µL
≈ 99 µL

21. On the tip of sterilized yellow-tip a part of each positive single colony from the
reference master agar plate was used to streak a numbered agar plate LB/Amp-Glu
and then placed inside a PCR eppendorf tube containing 96 µL of the above premix
solution, the tips kept for 15 min while the tubes were placed on ice.
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22. PCR runs was executed as per the following design:


Lid temperature:



Pre-cycle:



Thirty two cycle as follows:
•
•
•

105 ⁰C

95 ⁰C for 6 min (to activate the polymerase)

94 ⁰C

for

45 sec (denaturation)

for

45 sec (annealing)

72 ⁰C

for

45 sec (extension)

55 ⁰C



Post-cycle:



End cycle:

72 ⁰C for 10 min (final extension)
4 ⁰C

23. After PCR reaction, 10 µL from each sample were applied on a 1% agarose gel in
TBE and EtBr and run at 125 V for 30 min, and then the gel was visualized under a
UV trans-illuminator.
24. Hinf analysis was carried out to make a sub-selection from the positive clones, for
each sample a digestion mixture was prepared as follows:


Hinf (10 u/µL)

0.5 µL



10x Buffer R

1.1 µL



Total volume

1.6 µL

25. After filling the Westburg tubes with 1.6 µL of the premix, 10 µL of the colony PCR
reaction was added by means of a multichannel pipette, and then incubated at 37 ⁰C
for 1 h.

26. After incubation, 10 µL from each sample were applied on a 2% agarose gel in TBE
and EtBr and run at 110 V for 30 min, and then the gel was visualized under a UV
trans-illuminator.
27. According to the results obtained from Hinf analysis, each selected sample was
cleaned up for DNA sequencing using MP57 primer, as follows:


Colony PCR product

10 µL



ExoSAP-IT

2.6 µL



The mixture was incubated at 37 ⁰C for 15 min followed by another 15 min
at 80 ⁰C. Finally, the mixture stored at -20 ⁰C for sequencing.
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28. In addition, a corresponding colony of each positive clone was picked and incubated
overnight with shaking at 200 rpm at 37 ⁰C in LB medium with ampicillin (at final
concentration 100 µg/mL).

29. The next day, the recombinant pMECS phagemid (i.e. the plasmid) was purified
using GenElute Plasmid Miniprep kit as per the manufacturer protocol.
30. For each successfully identified VHHs sequence, their purified plasmids were used to
transform WK6 cells, for the expression of Nanobodies®, as previously described (see
Method 3.2.7.1 to 3.2.7.6).
Pause Point: A glycerol stock of the transformed WK6 cells must be made for the
prolonged storage of the VHHs of interest (Sambrook et al., 1989).
3.2.10 Expression and Purification of Antigen-Specific Binders
After transformation of the recombinant pMECS vector with the VHHs genes of interest into E.
coli WK6 cells, which lack suppressor (su-). Nanobodies® fused to HA-tag and His6-tag are
expressed and directed to the periplasm of the cells. The induced WK6 cells are exposed to an
osmotic shock to extract the periplasm. These extracts are purified via immobilized metal affinity
chromatography IMAC, the latter is very sufficient to do basic tests such as ELISA and Western
blot. Furthermore, they can be subsequently purified through size exclusion chromatography.
Procedure
1. A single colony of E. coli WK6 containing the plasmid of the VHH of interest was
used to inoculate a starter culture of 15 mL LB/Amp medium in 50-mL Falcon tube.
The culture was incubated overnight at 37 ⁰C while shaking at 200 rpm.

2. The next day, 1 mL of the starter culture was used to inoculate 330 mL TB/Amp-GluMg medium in a 1 L baffled shake flask and then the culture was incubated for 2-4 h,
with shaking at 200 rpm at 37 ⁰C until the OD600nm value reached 0.6-0.9.

3. Each 330 mL TB/Amp-Glu-Mg medium was induced with 330 µL 1M IPTG for a
final concentration 1 mM. Afterward, the culture was incubated overnight with
shaking at 200 rpm at 28 ⁰C until the OD600nm of the undiluted culture reached 20-30.

Finally, the culture was transferred to appropriate tubes for centrifugation at 11,300 g
for 8 min at 4 ⁰C.
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4. The supernatant of each 330 mL culture was decanted and the cell pellet was fully
suspended in 4 mL TES buffer through reciprocating pipetting. Subsequently, the
suspension was kept on ice in the cold room, at 4 ⁰C, on a shaker at 200 rpm for 6 h.

5. While cells still on ice 8 mL of 1/4th dilution TES buffer was added, and kept in the
cold room on ice and shaking at 200 rpm overnight.

6. The next day, all the tubes were centrifuged for 30 min at 11,300 g at 4 ⁰C and then

the supernatant containing the periplasmic extract was carefully transferred to 50-mL
Falcon tubes.

7. The PD-10 columns were prepared for IMAC purification of the His6-taged VHHs,
for each liter of E. coli culture 1 mL of the HIS-Select gel was used with binding
capacity of about 15 mg His-tag VHH/mL.
8. In the beginning, the HIS-Select gel was equilibrated with 50 mL PBS, then 40 mL of
the supernatant was discarded and the rest volume was equally distributed over the 50
mL Falcon tubes with the periplasmic extract. The mixture was incubated at 4 ⁰C for
30 min with gentle shaking.

9. After incubation, the mixture was poured into the PD-10 column with filter fitted
inside and was left to drain by gravity.
10. The His-Select gel washed with 20 column volumes with PBS until the last droplet
OD280nm value was close to zero.
11. The Ni-ion bound Nanobodies® was eluted by adding 5 columns volume of 500 mM
Imidazole in PBS, the elution continued until the last droplet OD280nm value was less
than 0.15.
12. Finally, the Ni-NTA fractions were ran on 12% sodium-dodecyl-sulfate polyacrylamide-electrophoresis gel (SDS-PAGE) to confirm Nanobodies® elution in the
samples. The fractions were pooled and their approximate protein concentration was
measured at OD280nm at their individual extinction coefficients’ values using
Nanodrop® spectrophotometer.
13. The Imidazole was replaced with PBS buffer by using Vivaspin column with
molecular weight cut off value MWCO of 5 kDa.
Caution: Nanobodies® eluted with Imidazole only stored at 4 C, freezing may cause
irreversible precipitation.
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4 Results and Discussion
4.1 Camel Immunization
In order to generate antigen specific HCAbs, a three years old camel of about 250 Kg weight,
was immunized with SmCB and SmES antigens. Medical follow up was performed on regular
basis. Evidently, no significant health problem occurred during the entire immunization period
until the blood withdrawing date (i.e. 8 weeks).

4.2 Library Construction
Lymphocytes of the immunized camel were extracted from 100 mL of peripheral blood PBL
using Leucosep™ tube. A total amount of about 40 µg mRNA was extracted from the PBL and
was subsequently used as a template for generating the first complementary strand of
complementary DNA. Afterward, the 1st cDNA was as a template to amplify the gene fragments
encoding for the variable domain of the heavy chain only antibodies and the conventional
antibodies up to the CH2 domain. The resultant fragments bands are corresponding to VH-CH1hinge-CH2 and VHH-hinge-CH2 regions of corresponding sizes of about ≈ 900 bp and ≈ 700 bp
respectively. Figure 1.14 illustrates the 1st PCR products and the resulting bands after separation
on 1% agarose gel electrophoresis.

Figure 1.14. 1st PCR products gel electrophoresis on 1% agarose gel. Both A & B represent the
amplification products of the 1st strand cDNA PCR containing fragments with two different sizes.
The red arrow points at the 900 bp fragment corresponds to VH-CH1-hinge-CH2, whereas, the
blue arrow points at the 700 bp fragment corresponds to VHH-hinge-CH2.
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The 700 bp fragment band purified from the 1% agarose gel using the QIAquick Gel
Extraction Kit (Qiagen), then the purified products used as a template for a nested PCR
amplification processes specific to VHH-only sequences producing a corresponding DNA
fragment of about 400 bp. Figure 1.15A illustrates the purified 700 bp band after purification,
while, Figure 1.15B represents the product of the 2nd nested PCR.

Figure 1.15. Purified and Nested PCR Products Gel Electrophoresis on 1% Agarose Gel. A.
the blue arrow points at the purified 700 bp fragment correspond to the VHH-CH2 region. B. the
blue arrow points at the product of the 2nd nested PCR of about 400 bp and correspond to the
VHH only fragment.
The PCR fragments and the pMECS vector were digested with the same restriction
enzymes via two consecutive digestion sessions. Figure 1.16 illustrates the digested purified 2nd
PCR product and the vector at two different volumes; 0.5 and 1 µL per lane (1 & 2) and (3 & 4)
respectively.

Vector

VHH
Figure 1.16. Digested VHH Fragment and Vector Gel Electrophoresis on 1% Agarose Gel.
The red arrow points at the digested pMECS vector, while, the blue arrow points at the VHH
fragment.
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The pMECS clean ligation was subsequently transformed into the freshly prepared
electrocompetent cells of Escherichia coli TG1 strain by electroporation. Finally, a library size
of about 1.2 x107 transformants (i.e. clones) was obtained. Figure 1.17 illustrates the products of
the colony PCR, from 30 randomly selected single colonies from the dilution plates, which
determined about 80 % (i.e. 24 clones with correct insert size out of 30 picked samples) of the
clones in the constructed library contained a correct insert size of about ≈ 700 bp encodes for the
bacteriophage gIIIp protein (≈ 300 bp) fused to the VHH (≈ 400 bp).

Figure 1.17. Colony PCR for Library with Correct Insert-Size Estimation. The blue arrows
point at the correct size, the lanes numbers between brackets signify those with incorrect sizes.

4.3 Screening and Isolation of Nanobodies®: Phage Display and Biopanning
After infecting the E. coli TG1 cells with M13K07 helper phage, a phage library which displays
VHHs on their tips was generated. These virions used for four consecutive rounds of biopanning
against the two antigens (i.e. SmCB and SmES). There was no significant enrichment in phages.
Nonetheless, random 47 single individual colonies of bacteria for each antigen were used for
screening antigen-specific VHHs via Periplasmic Extract ELISA (PE-ELISA). Only two
colonies corresponding to SmES gave (≥ 2) the reading absorbance value and were considered
positive, whereas, thirty six colonies corresponding to SmCB were considered positive, divided
into groups with regard to their absorbance intensities. Furthermore, the redundancy of the
ELISA-positive colonies was further screened for their redundancy by colony PCR, Hinfdigestion on single colonies and DNA sequencing.
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Table 1.11. PE ELISA Readings for SmCB Antigen-Specific VHH binders - Plate A & B
SmCB
Plate-A
A
B
C
D
E
F
G
H
SmCB
Plate-B
A
B
C
D
E
F
G
H
Where:

1

2

3

4

5

6

7

8

9

10

11

12

0,085
0,065
0,082
0,063
0,285
0,096
2,763
2,748

0,07
0,067
0,103
0,072
0,081
0,072
0,082
0,079

0,074
0,077
0,154
0,075
0,091
0,081
0,074
0,071

0,086
0,082
3,041
2,764
0,345
0,088
0,099
0,074

2,889
2,821
0,15
0,077
2,771
3,053
0,139
0,082

0,36
0,118
0,18
0,077
2,732
2,359
0,112
0,087

0,126
0,084
3,032
2,918
0,38
0,106
0,074
0,083

1,458
1,406
2,46
2,281
0,319
0,107
2,359
1,821

0,108
0,088
0,091
0,08
0,177
0,083
0,079
0,082

0,1
0,089
0,257
0,078
0,217
0,085
0,139
0,082

0,097
0,088
0,123
0,077
2,802
2,608
0,167
0,075

3,031
2,812
0,13
0,079
0,347
0,118
0,203
0,078

1

2

3

4

5

6

7

8

9

10

11

12

0,201
0,111
0,112
0,103
0,107
0,081
3,524
3,398

0,346
0,152
0,438
0,219
0,146
0,082
0,095
0,085

0,263
0,115
0,344
0,248
0,302
0,095
0,102
0,083

0,221
0,124
0,837
0,653
0,38
0,125
0,5
0,227

0,196
0,12
0,29
0,234
0,316
0,094
2,229
1,687

0,183
0,157
0,345
0,147
0,445
0,117
0,349
0,082

0,128
0,131
0,334
0,178
2,824
2,321
0,288
0,083

3,158
2,69
0,3
0,149
0,244
0,081
0,098
0,081

0,164
0,147
0,354
0,227
0,259
0,079
0,122
0,078

0,11
0,192
0,224
0,104
0,453
0,245
0,107
0,08

0,262
0,143
1,053
0,709
0,118
0,079
0,303
0,102

0,193
0,122
0,194
0,083
0,163
0,081
2,841
2,563

Group 1
Group 2
Negative Control

Group 3
Group 4
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Table 1.12. PE ELISA Readings for SmES Antigen-Specific VHH binders - Plate A & B
SmES
Plate-A
A
B
C
D
E
F
G
H
SmES
Plate-B
A
B
C
D
E
F
G
H
Where:

1

2

3

4

5

6

7

8

9

10

11

12

1,289
0,773
3,459
3,477
3,543
3,312
3,65
3,41

3,069
3,172
3,373
3,373
3,54
3,31
3,479
3,201

3,425
3,397
0,358
0,232
3,268
3,422
0,104
0,086

3,206
3,242
3,398
3,122
3,29
2,93
3,12
2,986

3,004
2,947
3,259
3,346
0,462
0,151
3,242
3,346

3,006
2,708
2,797
2,924
3,089
3,185
3,389
2,94

0,881
1,066
3,178
2,751
2,824
2,919
3,315
2,676

2,868
3,122
3,025
3,022
2,8
3,178
3,212
2,871

2,835
2,888
2,741
2,639
2,912
2,743
2,531
2,629

0,688
0,856
0,945
0,657
2,974
2,729
2,966
2,571

2,823
2,508
0,094
0,087
2,626
2,481
2,854
2,551

0,084
0,087
3,586
2,555
2,745
2,707
2,89
2,649

1

2

3

4

5

6

7

8

9

10

11

12

3,349
3,224
3,106
3,382
3,23
3,078
3,26
3,115

3,218
3,423
3,427
3,16
3,224
3,129
3,341
3,228

2,935
3,144
0,374
0,293
1,824
1,752
3,28
3,193

3,282
2,886
3,13
3,052
2,997
3,009
3,193
3,068

3,318
3,32
3,773
3,312
0,375
0,097
1,343
1,046

1,901
2,199
3,515
3,408
1,94
2,012
3,124
2,946

3,249
3,463
3,464
3,277
3,693
3,184
3,451
3,011

3,364
3,59
1,809
1,629
3,46
2,869
3,904
2,787

3,116
3,509
2,538
3,15
3,937
3,139
3,227
2,932

2,628
3,062
2,875
3,108
3,02
3,08
2,972
3,016

0,258
0,283
1,049
1,035
2,469
2,662
3,38
3,158

2,818
3,963
2,839
2,754
3,19
2,786
2,2
1,546

Group 1
Negative Control
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Figure 1.18 illustrates the colony PCR products of three sample clones for SmES antigen (i.e.
two positive binders and one random), and all the positive selected binders of SmCB. Five clones
seemed to be contaminated and didn’t offer any good candidate, whilst, thirty seven clones were
found with the correct insert size and were put forward for further Hinf-digestion analysis.

Figure 1.18. Colony PCR for Selected Binders from PE ELISA. From E1 to E3 are colonies
for the SmES two positive binders and one negative sample which was randomly selected. From
C1 to C39 are colonies for the SmCB positive binders.
All the positive colonies were subjected for further Hinf-digestion in order to assort the positive
clones into groups. Figure 1.19 illustrates the results after digestion.

A

BA C D C E A B C F GH G

Figure 1.19. The Products of Hinf-Digestion. There are eight different groups of positive
clones.
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All the positive clones were sent for sequencing and then all sequences were translated into their corresponding amino acids using Clone
Manager-6 program. The produced amino acids sequences were aligned and divided into groups, using ClustalW2 multiple sequence
alignment program. Noteworthy, some of the binders’ retrieved sequences were omitted, and are not shown here in the study, due to
inadequacy and erratic manner of their results; mostly it occurs while sequencing, and clones should go for another attempt:
NbSmCB6

<------------------FR1-----------------> <---CDR1---> <------------FR2----------->
QVQLQESGGGSVQAGGSLRLSCTVSG

ETYRSRY

LAWFRAAPGKEREGVAVI

NbSmCB2
NbSmCB3
NbSmCB25
NbSmCB11
NbSmCB13
NbSmCB14
NbSmCB15
NbSmCB27
NbSmCB11
NbSmCB13
NbSmCB14
NbSmCB15
NbSmCB27

LPGGGTTY

<--------------------------FR3---------------------------> <------------CDR3------------> <------FR4------>
YTDSVKGRFTISQDIPKTTVYLQMNSLKPEDTAMYYC

NbSmCB2
NbSmCB3
NbSmCB25

<---CDR2--->

AASTSMYLYDRKFSADAYNY

<------------------FR1-----------------> <-CDR1->
QVQLQESGGGSVQAGGSLKLSCTASG
QVQLQESGGGSVQAGGSLKLSCTASG
QVQLQESGGGSVQAGGSLKLSCTASG

WGQGTQVTVSS

<-------------FR2------------> <---CDR2--->

YIYKTF
YIYKTF
YIYKTF

WGWFRQAPGKEREGVALF
WGWFRQAPGKEREGVALF
WGWFRQAPGKEREGVALF

ATDGIYID
ATDGIYID
ATDGIYID

<--------------------------FR3---------------------------> <------------CDR3-----------> <------FR4------>
YADSVKGRFTISTDNVKNTVYLMMTNLKPEDTAIYYC
YADSVKGRFTISTDNVKNTVYLMMTNLKPEDTAIYYC
YADSVRGRFTISTDNVKNTVYLMMTNLKPEDTAIYYC

AAGFGGDYSRRWQIGSWIY
AAGFGGDYSRRWQIGSWIY
AAGFGGDYSRRWQIGSWIY

<------------------FR1-----------------> <-CDR1-> <------------FR2------------>
QVQLQESGGGSVQAGGSLRLSCKASS
QVQLQESGGGSVQAGGSLRLSCKASS
QVQLQESGGGSVQAGGSLRLSCKASS
QVQLQESGGGSVQAGGSLRLSCKASS
QVQLQESGGGSVQAGGSLRLSCKASS

YTGI
YTGI
YTGI
YTGI
YIGI

WGRGTQVTVSS
WGRGTQVTVSS
WGRGTQVTVSS

<---CDR2--->

MAWFRQSLGKEREGVAAI
MAWFRQSLGKEREGVAAI
MAWFRQSLGKEREGVAAI
MAWFRQSLGKEREGVAAI
MAWFRQSPGKEREGVAAI

RTGTHETY
RTGTHETY
RTGTHETY
RTGTHETY
RTGTHGTY

<--------------------------FR3----------------------------> <-----------CDR3-----------> <------FR4------->
YHDSVKGRFTISRDNAEKTVYLQMNSLKPEDTAMYYC
YHDSVKGRFTISRDNAEKTVYLQMNSLKPEDTAMYYC
YHDSVKGRFTISRDNAEKTVYLQMNSLKPEDTAMYYC
YHDSVKGRFTISRDNAEKTVYLQMNSLKPEDTAMYYC
YDDSVKGRFTISRDNAENTVYLQMNSLKPEDTAMYYC

AAARLSVYEWYSDSRYNF
AAARLSVYEWYSDSRYNF
AAARLSVYEWYSDSRYNF
AAARLSVYEWYSDSRYNF
AAARLSVYEWYSDSRYNF

WGQGTQVTVSS
WGQGTQVTVSS
WGQGTQVTVSS
WGPGTQVTVSS
WGQGTQVTVSS
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NbSmCB10
NbSmCB17
NbSmCB18
NbSmCB19
NbSmCB20
NbSmCB21
NbSmCB22
NbSmCB28
NbSmCB29
NbSmCB30
NbSmCB10
NbSmCB17
NbSmCB18
NbSmCB19
NbSmCB20
NbSmCB21
NbSmCB22
NbSmCB28
NbSmCB29
NbSmCB30
NbSmCB8
NbSmCB16
NbSmCB8
NbSmCB16

<------------------FR1-----------------> <-CDR1-> <-------------FR2------------->
QVQLQESGGGSVQAGGSLRLSCVAST
QVQLQESG??SVQAGGSLRLS?VAST
QVQLQESGGGSVQAGGSLRLSCVAST
QVQLQESGGGSVQAGGSLRLSCVAST
QVQLQESG?GSVQAGGSLRLS?VAST
QVQLQESGGGSVQAGGSLRLSCVAST
QVQLQESGGGSVQAGGSLRLSCVAST
QVQLQESGGGSVQAGGSLRLSCVAST
QVQLQESGGGSVQAGGSLRLSCVAST
QVQLQESGGGSVQAGGSLRLSCVAST

YTYTS
YTYTS
YTYTS
YTYTS
YTYTS
YTYTS
YTYTS
YTYTS
YTYTS
YTYTS

<---CDR2--->

MGWFRQAPGKEREGVASI
MGWFRQAPGKEREGVASI
MGWFRQAPGKEREGVASI
MGWFRQAPGKEREGVASI
MGWFRQAPGKEREGVASI
MGWFRQAPGKEREGVASI
MGWFRQAPGKEREGVASI
MGWFRQAPGKEREGVASI
MGWFRQAPGKEREGVASI
MGWFRQAPGKEREGVASI

NSRFNTNTY
NSRFNTNTY
NSRFNTNTY
NSRFNTNTY
NSRFNTNTY
NSRFNTNTY
NSRFNTNTY
NSRFNTNTY
NSRFNTNTY
NSRFNTNTY

<--------------------------FR3----------------------------> <-----------CDR3-----------> <------FR4------->
YADSVKGRFTISRDSAKNTVYLQMNSLKPEDTAIYYC
YADSVKGRFTISRDSAKNTVYLQMNSLKPEDTAIYYC
YADSVKGRFTISRDSAKNTVYLQMNSLKPEDTAIYYC
YADSVKGRFTISRDSAKNTVYLQMNSLKPEDTAIYYC
YADSVKGRFTISRDSAKNTVYLQMNSLKPEDTAIYYC
YADSVKGRFTISRDSAKNTVYLQMNSLKPEDTAIYYC
YADSVKGRFTISRDSAKNTVYLQMNSLKPEDTAIYYC
YADSVKGRFTISRDSAKNTVYLQMNSLKPEDTAIYYC
YADSVKGRFTISRDSAKNTVYLQMNSLKPEDTAIYYC
YADSVKGRFTISRDSAKNTVYLQMNSLKPEDTAIYYC

AAGPLQGGVTWDKPSGYTR
AAGPLQGGVTWDKPSGYTR
AAGPLQGGVTWDKPSGYTR
AAGPLQGGVTWDKPSGYTR
AAGPLQGGVTWDKPSGYTR
AAGPLQGGVTWDKPSGYTR
AAGPLQGGVTWDKPSGYTR
AAGPLQGGVTWDKPSGYTR
AAGPLQGGVTWDK?SGYTR
AAGPLQGGVTWDKPSGYTR

<------------------FR1-----------------> <--CDR1--> <------------FR2------------>
QVQLQESGGGSVQDGGSLRLSCVASG
QVQLQESGGGSVQDGGSLRLSCVASG

YTYSIKW
YTYSIKW

RGWFRQAPGKEREAVAAI
RGWFRQAPGKEREAVAAI

WGQGTQVTVSS
WGQGTQVTVSS
WGQGTQVTVSS
WGQGTQVTVSS
WGQGTQVTVSS
WGQGTQVTVSS
WGQGTQVTVSS
WGQGTQVTVSS
WGQGTQVTVSS
WGQGTQVTVSS

<---CDR2--->
GTGSGATY
GTGSGATY

<--------------------------FR3----------------------------> <-----------CDR3----------> <------FR4------->
YDDSVRGRFTISQDNAQNTVYLQMSSLKPEDTALYYC
YDDSVKGRFTISQDNAQNTVYLQMSSLKPEDTALYYC

AASDSQSFLLTRSDRYKY
AASDSQSFLLTRSDRYKY

WGQGTQVTVSS
WGQGTQVTVSS
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<------------------FR1-----------------> <-CDR1-> <------------FR2------------->

NbSmCB9

QVQLQESG??SVQAGGSLRLSCEASG

NbSmCB9

YADSVKGRFTISRDNAKNVVYLQMNNLKPEDTAIYYC

YNISTYC

ATNSLWCPGFQASRWNY

<------------------FR1-----------------> <-CDR1-> <------------FR2------------->
QVQLQESG?GSVQAGGSLRLSCAASG
QVQLQESGGGSVRAGGSLRLSCAASG

NbSmCB7
NbSmCB26

YADSV??RFTISRDY?KMTVDLQMNNL?PDDTGMYYC
YADSVKGRFTISRDYAKMTVDLQMNNLKPDDTGMYYC

NbSmES1
NbSmES2
NbSmES3
NbSmES5
NbSmES4
NbSmES4

GSSGGRTY

<--------------------------FR3----------------------------> <-----------CDR3-----------> <------FR4------->

NbSmCB7
NbSmCB26

NbSmES1
NbSmES2
NbSmES3
NbSmES5

<---CDR2--->

MGWFRQAVGKEREGVANI

YTSAPY?
YTSAPYL

WGQGTQVTVSS

<---CDR2--->

MGWL???VPGKECESVSS?
MGWL?RQVPGKECESVSSM

?TAGFPN
STAGFPN

<--------------------------FR3----------------------------> <-----------CDR3----------> <------FR4------->
A?SGRWRC
AASGRWRC

<------------------FR1-----------------> <-CDR1-> <------------FR2------------>
QVQLQESGGGSVQAGGSLRLSCAASG NSRRPLKY
QVQLQESGGGSVQAGGSLRLSCAASG NSRRPLKY
QVQLQESGGGSVQAGGSLRLSCAASG NSRRPLKY
QVQLQESGGGSVQAGGSLRLSCAASG NSRRPLKY

IGWFRQPPGKEREGIAAI
IGWFRQPPGKEREGIAAI
IGWFRQPPGKEREGIAAI
IGWFRQPPGKEREGIAAI

DGQGTQ?TVSS
DGQGTQVTVSS

<---CDR2--->
HLAGGSTW
HLAGGSTW
HLAGGSTW
HLAGGSTW

<--------------------------FR3----------------------------> <-------------CDR3------------> <------FR4------->

YSDSVKGRFTISQDRDKNTVYLQMNSLKPEDTAIYYC
YSDSVKGRFTISQDRDKNTVYLQMNSLKPEDTAIYYC
YSDSVKGRFTISQDNAKNVVYLQMNSLKPEDTAIYYC
YSDSVKGRFTISQDRDKNTVYLQMNSLKPEDTAIYYC

AALSKSRVGYWRSSREYKY
AALSKSRVGYWRSSREYKY
AALSKSRVGYWRSSREYKY
AALSKSRVGYWRSSREYKY

<------------------FR1-----------------> <--CDR1--> <------------FR2------------->
QVQLQESGGGSVQAGGSLRLSCAASG

NTDN-IYR

MTWFRQAPGKEREGVASM

WGQGTQVTVSS
WGQGTQVTVSS
WGQGTQVTVSS
WGQGTQVTVSS

<---CDR2--->
QRNGRGIY

<--------------------------FR3----------------------------> <-------------CDR3------------> <------FR4------->
YANSVKGRFTISQDNAKNTLYLQMNSLKPEDTGVYYC

TT-------GWRALRLLP-

DRRGTQVTVSS

Where:
FR1,2,3,4: Fram Works 1, 2, 3 and 4
CDR1,2,3: Complementarity Determining Regions 1, 2 and 3
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4.4 Expression and Purification of Antigen-Specific Binders
The recombinant pMECS vector with the VHHs genes of interest were transformed into E. coli
WK6 cells, which lack suppressor (su-). Nanobodies® fused to HA-tag and His6-tag are
expressed and directed to the periplasm of the cells. The induced WK6 cells are exposed to an
osmotic shock to extract the periplasm. These extracts are purified via Ni-NTA immobilized
metal affinity chromatography IMAC. The eluted Ni-NTA fractions were pooled and ran on
sodium-dodecyl-sulfate poly acrylamide electrophoresis gel (SDS-PAGE), using 12% SDS
bistris gel (Invitrogen), to confirm the expression.
As a final point, the approximate protein concentration was measured at OD280nm at their
individual extinction coefficients’ values using UV Nanodrop® spectrophotometer. Figure 1.20
illustrates an SDS-PAGE results for one of the produced binders, a systematic follow-up for the
presence of the VHH along with the entire processes.

Figure 1.20. VHHs Presence and Purity Confirmation via 12% SDS-PAGE. M. Page Ruler™
Prestained Protein Ladder (Fermentas). 1. First flow-through of IMAC, 2. Native PE extract, 3.
Second flow-through of IMAC, and 4. IMAC purification of PE extract of one of the expressed
Nanobodies®. All the Nanobodies® were displayed as a single band of approximately 15 kDa
matching their theoretical molecular weight values.
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Information about the physical properties of the selected Nanobodies® is necessary for
further experimental set-ups, they were obtained based on the amino-acid sequences of each
VHH protein, including the peptide tags, using the ProtParam tool at the ExPASy proteomics
server of the Swiss Institute of Bioinformatics.
Table 1.13. Physical properties & final concentrations of SmCB and SmES specific Nanobodies®
VHH Name

Number of amino acids

Molecular

(including HA & His6 tag) weight (Da)

Theoretical

Extinction

Yield

pI

coefficient

(mg/L)

NbSmCB2

144

16004.7

7.17

2.835

8.47

NbSmCB9

141

15624.1

7.86

2.457

5.85

NbSmCB10

144

15734.2

8.56

2.090

8.91

NbSmCB11

141

15809.3

7.25

2.175

8.98

NbSmCB16

144

15843.2

6.64

2.170

2.01

NbSmCB26

133

14387.9

7.16

1.697

12.9

NbSmES4

137

15194.8

9.39

1.606

0.1

NbSmES5

146

16226.9

9.39

2.366

1.2
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5

Conclusion

There are over 200 million people worldwide infected with Schistosomiasis, 120 million
symptomatic patients and 600 million individuals live at risk, in addition, there are 280,000 of
new cases every year mostly among the world’s poorest populations where they lack the
infrastructure and resources necessary to establish proper equipped laboratories for diagnosis and
treatment. Given the high risk of complications, and for further extent, mortality due to Bilharzia,
a rapid and accurate schistosoma diagnosis is critical for the appropriate treatment of affected
individuals. In the study presented here, we wanted to establish a sensitive technique for
detecting parasite specific antigen utilizing Nanobodies® to be used as molecular imaging
diagnostic and a therapeutic agent for a novel immunotherapeutic approach.
Currently, there are more than 20 therapeutic mAb products on the healthcare market and
more than 100 in clinical trials, it is logical that engineered antibodies have come of age as
biopharmaceuticals candidates (Reichert, 2008). Despite various beneficial characteristics of the
conventional antibodies, the low intrinsic toxicity of the Nanobodies® together with their size
characteristics and their high specificity and affinity for the antigen render them more proficient
tools for various approaches – e.g. anti-biomarkers, drug delivery, in addition, physo and
chemotherapeutic agents.
In this study, we could successfully generate different Nanobodies® against two
representative schistosoma antigens (i.e. S. mansoni Cathepsin B and Execratory Secretory
antigens). Consequently, the obtained data suggests that these anti-schistosoma Nanobodies® can
be properly designed for being used as a premier molecular research tool with the aim of
unraveling the in vivo molecular mechanism of the host cell invasion. Moreover, wide range of
novel Bio-Nano-Conjugate systems can be constructed with metallic, polymeric and magnetic
nanoparticles for creating state-of-the-art healthcare theragnostic tools. For instance, rapid lateral
flow assays, surface plasmonic resonance, colorimetric tests, magnetic concentrating technique,
magnetic targeting and magneto hyperthermia applications.
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CHAPTER 2: CONSTRUCTION OF 99mTC LABELED-sdAb-GRAPHENECOATED-NANOMAGNET BIOCONJUGATE – PROOF OF CONCEPT
1 Magnetism: BioNanosystems for Magnetic enforced-Active-Targeting
1.1 Nano-Magnetism from Ferro to Superparamagnets: The Prologue
The etiology of magnetism is an old science that withdrawn an immense attention and interest
during the past centuries. The phenomenon exists in a material, commonly a metal, when the
electrons of a typical atom rotate around it’s nucleus in a certain radius – r and angular velocity –
ω. The atomic number – Z determines the total number of electrons and the charge of each
electron is given by a value of (e). In general, when a charged particle is in motion around a
circular path it generates an electric current with a total amplitude value equals (µoIA), where
(A) is the area enclosed of the circular motion of each electron, it equals (A = πr2), and (I) is the
generated current’s intensity, it equals (I = -eω/2π). The produced magnetic moment generated
by the motion of the charged electron around the atomic circular path, which is typically an
orbital motion, is given by:
𝝁𝝁ₒ𝒆𝒆𝒆𝒆𝒓𝒓𝟐𝟐
𝑴𝑴 = −
𝟐𝟐
When the outermost shell(s) of an atom are not completely filled they have permanent net

magnetic moments. These moments are created from the summation and subtraction of the
combination of the total spin and orbital motions of its electron(s). Generally, the actual
magnetism of these numerous number of electrons has insignificant values, because of their
intrinsic random path orientations inside the magnetic matter. Nevertheless, when exposed to
external magnetic/electric fields, the magnetic dipole moments generated from the randomly
moving electrons align themselves in a way that creates a net magnetic field in a certain direction
matching the one of the externally applied field. A ferromagnetic material has a natural magnetic
moment, which implies that the components of the electron moments and the orbital motion’s
moments are arranged parallel to each other. This spontaneous magnetisation is temperature
dependant (i.e. it vanishes above Curie temperature). As the temperature increases, thermal
motion, or entropy, competes with the ferromagnetic tendency for dipoles to align, and a
ferromagnetic material becomes paramagnetic (i.e. the magnet will lose its magnetism)
(Balakrishnan, 2011).
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For instance, the Curie temperature of some common materials is: Iron (Fe) 770 ⁰C, Cobalt (Co)
1130 ⁰C, Nickel (Ni) 358 ⁰C and Iron Oxide (Fe2O3) 622⁰C (Buschow, 2001).

Figure 2.21. Illustration of Ferromagnetic Domains (Harris, 2002)
A typical ferromagnetic material reaches its magnetisation saturation when it is exposed
to external magnetic field. Figure 2.22 illustrates the classical hysteresis curve obtained
throughout the magnetizing and demagnetizing process of a bulk unmagnetized ferromagnetic
material. In the absence of any external magnetic field, the magnetic moments of the same
orientation are intrinsically organized in regions called magnetic domains which are separated by
virtual barriers know as “domain walls”. Each of these domains has a permanent net
magnetisation (M) in a certain direction. Although, the orientation of the domains in the bulk
material is random it results in an innate net magnetisation value (Figure 2.22a), a more
energetically favorable configuration. Upon exposure to a sufficiently large external magnetic
field, the domains with magnetisation direction all along the magnetic field axis enlarge while
the others get smaller in a phenomenon known as “domain wall displacement” (Gubin et al.,
2005) (Figure 2.22b). The alignment continues until all moments are aligned in the direction
corresponding to that of the external field (Figure 2.22c) at this configuration the material
reaches its magnetisation saturation (Ms). When the external field is removed the materials’
magnetisation does not relax-back to the initial state. However, some energy is stored
maintaining a net magnetisation known as “remanent magnetisation” (Mr). An external magnetic
field of a definite magnitude must be applied in the opposite direction in order to demagnetize
the material and reduce its magnetisation back to zero that is known as coercivity field (Hc).
Continuing to expose the material to the opposite field, the same behavior is observed but in
opposite manner. Hysteresis refers to the inability of retracing the magnetisation curve, since the
material retains a memory of its magnetisation (Mr) (Balakrishnan, 2011).
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Figure 2.22. Hypothetical Domain Configuration and Hysteresis Loop of an Unmagnetized
Ferromagnetic Material (Taylor, 2010)
In nanoscaled magnetic particles, the above scenario diametrically opposed, at a certain
nano-size limit particles become so small that they consist of a single domain, leading to the
emergence of a distinctive phenomenon known as “Superparamagnetism”, in which
nanoparticles are found superior to ferromagnetic particles due to the absence of remanent
magnetisation. These particles reveal magnetic properties only in the presence of an external
magnetic field (Giri, 2003). In the case of single domain magnetic particles the difference
between the minimum and maximum potential energy per unit volume of the particle’s magnetic
moment is significantly smaller than its thermal energy. Consequently, the orientations of these
magnetic moments are in constant change due to the thermal agitation. Therefore, thermal energy
becomes large enough to cause random fluctuation in the absence of any external fields (Taylor,
2010). Thus, nanosized particles seem to lack hysteresis loss, nevertheless, their coercivity value
does not rest at zero, various theoretical calculations indicate that this happens for different
particles in different size ranges, for instance, 15-30 nm for Fe, 70 nm for Co and 32-55 nm for
Ni (Gubin et al., 2005).
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Figure 2.23 illustrates the change in coercivity value as a function of particle diameter. Where:
(Dcrt) is the particles’ critical diameter and (Dsp) is the superparamagnetic diameter.

Figure 2.23. Coercivity as a Function of Particle Diameter (Ashby et al., 2009)
Figure 2.24 illustrates the magnetisation curve of superparamagnetic particles, in which, there is
no hysteretic nature of the curve and a very small coercivity field magnitude exists (Taylor,
2010).

Figure 2.24. Hypothetical Magnetisation Curve of Common Superparamagnetic
Nanoparticles (Taylor, 2010)

1.2

Carbon Nanostructures: Graphene-Encapsulated Nanomagnets

The implementation of the extraordinary properties of superparamagnetic nanoparticles is
hindered by many factors that limit their applications. The chemical stability is one of the most
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critical factors where they are used in complex fluid systems – e.g. biological fluids. In addition,
dispersion concerns are also a crucial factor, in view of the fact that, most of the nanoparticles
will tend to aggregate in order to minimize their surface free energy. Furthermore, nanoparticles
are easily oxidized in presence of free oxygen, therefore, they might lose partially or entirely
their significant magnetisation. As a result, numerous attempts have been devoted to furnish
these nanomagnets with appropriate protection through encapsulation into an inert chemical
compounds – e.g. consecutive graphene layers (Mahmood et al., 2009).
Various coating materials were successfully employed, for example, gold, silica,
transition-metal oxides and carbon-encapsulations. The use of gold cannot be recognized as an
economic-friendly approach. The covalent bonds on silica and other transition-metal oxides are
prone to hydrolysis due to the instability of the silica shells under prolonged exposure to basic
conditions. Finally, a carbon coating is considered as the most promising option. Graphene is
recognized as one of the most stable materials on earth, in addition, it only requires a single
nanometer of carbon encasing the produced nanomagnets (Grass et al., 2007).

Figure 2.25. Graphene-Coated Nanomagnete. Carbon Encasing Magnetic nanoparticles with
two to four layers of graphitic carbon, TEM image of the nanoparticles (Mahmood et al., 2009)
In addition to the protective function of coating to preserve the favorable properties of the
magnetic core, graphene also offers a foundation for functionalizing the nanomagnets via
attaching complex structures of a huge range of biomolecules. For instance, proteins, antibodies,
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DNA and mRNA (Herrmann et al., 2009). The binding strength between the nanomagnet and the
surface active molecules is so vital and it determines the overall performance. In actual fact, the
carbon-carbon bond which constructs the backbone of almost all biological compounds is
recognized as the strongest and most reliable chemical bond (Schätz et al., 2010).

1.3 The Superiority of Graphitic Nanomagnets
Conventional protection via thick polymer layers is available only in the micrometer-size, which
is recognized as a sharp contrast to the final size obtained by coating with single nanometer layer
of single or multiple graphene layer(s) (Herrmann et al., 2009).
The limited magnetisation strength of the traditionally used metal oxides – e.g. iron
oxides, is comparatively much lower than that of pure metals. Whilst, encapsulating pure
magnetic metal inside the graphene coating grants an undiluted magnetisation and exceptionally
improves the strength and reactivity (Grass et al., 2007).
Graphene-coated nanomagnets have showed exceptionally high chemical stability under
sever harsh conditions. Hermann and Stark at ETH Zurich investigated the thermal and chemical
stability of the non-oxidic iron core-shell nanomagnets (i.e. iron carbide). About 80 wt % of the
as-grown-carbon-coated iron carbide nanomagnets were successfully recovered after incubation
for seven days in about 24 v% aqueous hydrochloric acid (i.e. pH<1). X-ray diffraction analysis
confirmed that no phase transition occurred. Quite the opposite, naked magnetite readily
dissolves within few seconds under similar strong acidic conditions (Herrmann et al., 2009).
Dispersion is considered as one of the main challenging obstacles in biomedical
applications, a variety of chemical adaptations have been theoretically and practically studied to
exploit the solubility and dispersion of carbon nanostructures and overcome their tendency of
aggregation. Well-designed surface engineering not only improves the dispersion efficiency but
also develops their biocompatibility and enhances their capability to demonstrate high
permeability and retention – EPR, which additionally improves their cellular uptake. The most
important approaches for these modifications are generally categorized into two major groups (a)
Covalent addition of chemical groups via reactions onto the π- conjugated skeletal structure of
the graphene-coat and (b) Non-covalent adsorption of the supra-molecular groups, e.g. biomolecules, peptides and proteins (Tasis et al., 2006; Liang & Chen, 2010).
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Recently, large numbers of in vitro and in vivo trials were performed in order to evaluate
the potential cellular uptake of carbon-coated magnetic nanostructures and explore the
relationships between their surface chemistry and biocompatibility. Professor Hwang and his
group from Shandong University, in collaboration with St. Jude Children’s Research Hospital,
USA, established a state-of-the-art experimental design in which they synthesized polymer
grafted carbon-coated metallic iron nanoparticles with various surface chemistry modifications
and investigated their oxidative stress, dynamic cellular response, cellular uptake and their
effects on triggering cell apoptosis. Fruitfully, most of the surface modified carbon-coated iron
nanoparticles presented high cellular uptake and insignificant cytotoxic effects which is
considered as a great promise for widespread biomedical applications (Mua et al., 2010).

1.4 Bioconjugation: Covalent and Non-Covalent Labeling
1.4.1

Covalent Labeling

Handling the as-produced carbon-coated nanostructures with a mixture of nitric acid and sulfuric
acids was found effective to convert most of the terminal carbons, and the carbons at the defect
site, into carboxylic groups (Wu et al., 2009). Subsequently, there are countless functional
groups can be attached to these carboxylic ends and make possible of a wide range of bioactive
compounds. The esterification of these carboxylic terminals may lead to high solubilization.
However, these soluble oxidized structures still tend to aggregate in presence of salts because of
charge-screening effects. Accordingly, they cannot be straightforwardly used for in vivo
applications due to the expected high salt-content of most biological fluids, and also because
further surface adjustments will be required. (Liu et al., 2009).
Fluorination of the side-walls of the graphene-coated nanostructures takes place via a
simple addition reaction. Such approach is considered very useful because further groups still
can be attached through substitution of fluorine with various groups. For instance, alkyles,
diamines and diols. Such amino alkylated surface can undergo further sophisticated
functionalization utilizing these free amino groups in order to bind to many biological molecules
for specific bio-medical applications (Wu et al., 2009).
Cycloaddition is considered as one of the most widely used covalent addition reactions
used to functionalize and efficiently disperse graphene-based nanostructures for biomedical
applications. For instance, addition of azides takes place at the native aromatic side-walls of the
81

graphene outer-walls. Finally, addition of terminal amine-terminated poly ethylene glycols can
be designed for biological applications (Liu et al., 2009).
1.4.2

Non-Covalent Labeling

Non-Covalent functionalization of carbon-coated nanostructures is usually accomplished by
coating with surfactants and polymers of amphiphilic nature, given that the chemical structure of
the π-network of the outermost graphene-layer is not affected. The characteristic poly-aromatic
nature of the graphitic surface is easy to get-linked-to via numerous aromatic molecules by the
aid of the π-π stacking. A notable study by Chen and Hongjie Dai at Stanford University showed
that proteins can be firmly attached to the surface of hollow cylinders of rolled-graphene-sheet,
i.e. single wall carbon nanotubes (SWNTs), functionalized by an amine-reactive pyrene
derivative (Chen et al., 2001). Accordingly, aqueous solutions of the non-covalently bioengineered molecules’ show high potential for numerous biomedical applications particularly
imaging, ultra high sensitive bio-sensoring and therapeutics (Wu et al., 2009; Liu et al., 2009).

1.5 Diagnostic Applications: Thermoacoustic Imaging
A variety of computerized tomographic techniques have had a massive impact on biomedical
diagnostics. Furthermore, numerous methods are being developed (e.g., the “common” X-ray,
single-photon emission, positron emission, ultrasound, magnetic resonance…etc) (Natterer,
1986). The never-ending strive is to increase the resolution and contrast of the imaging
techniques, and at the same time to reduce their cost and negative side-effects. Nonetheless,
these objectives are usually contradictory. For example, some economical and significantly
harmless techniques with high-resolution methods (e.g. ultrasound imaging) often do not provide
good contrast in soft tissues, whereas, other techniques with good contrast (e.g. optical or
electrical impedance tomography) suffer from low resolution. Recently, many researchers have
been working on developing novel generations of hybrid techniques. Thermoacoustic
tomography (TAT) is recognized as the most successful example of such hybridization
approaches (Kruger et al., 2003).
In TAT, a short-duration electromagnetic EM pulse is propelled through a biological
object (e.g. abdominal cavity, skull or a woman’s breast). These EM waves will trigger the
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generation of a thermoacoustic signal that can be detected via suitable transducers. Figure 2.26
illustrates the production of the thermoacoustic signal.

Figure 2.26. Thermoacoustic Signal Production. EM energy in is absorbed, producing heating,
followed by sudden thermal expansion, which induces an outwardly propagating acoustic wave
(Kruger et al., 2000)
However, as a diagnostic tool neither radiofrequency RF waves nor visual light alone
would provide acceptable resolution: (a) in case of RF, this is due to the long wavelength, yet,
shorter microwaves still can be used, although this will drastically affect their penetrability, (b)
in case of the optical region, the problem is with the multiple scattering of light. The absorption
of the EM energy results in thermo-elastic expansion, and thus, a pressure wave which is a
function of time and space/distance is generated. Such ultrasound signal can be measured by
transducers placed around the object in a three dimensional setup. Indeed, the measuring scheme
that utilizes two types of waves combines the high resolution of the ultrasound with the high
contrast of EM waves. The advantages of using microwave induced thermoacoustic imaging
MITI are utterly based on the simple relation (λ = c / ƒ). Where, frequency – ƒ which is inversely
proportional to the wavelength – λ – i.e. smaller wavelength results in better resolution, and the
speed of light and sound in air are approximately 3 x 108 m/s and 330 m/s respectively.
Therefore, MITI combines the privilege of both higher frequency and lower speed for better
resolution, in addition, takes advantage of both pure ultrasound imaging and microwave imaging
in order to obtain good spatial resolution and imaging contrast as well.
In seeking higher resolution and contrast for early, and yet accurate, detection of various
diseases many attempts are ongoing for in vivo contrast enhancement. A notable study by Nie et
al. showed fivefold great thermoacoustic signal enhancement and much longer retention time.
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When tumor bearing mice was intravenously injected with superparamagnetic magnetite
nanoparticles coated with polyaniline and conjugated to folic acid which serves as a cancerbiomarker-specific targeting ligand FA-Fe3O4/PANI (Nie et al., 2010). In conclusion, optimizing
the design of the conjugate system – i.e. targeting ligand (e.g. sdAbs), magnetic material (e.g.
Fe@C-MNP) and biocompatible coating (e.g. PEG and others) would have a tremendous impact
on the quality of the diagnostic processes and subsequently on the efficacy of the therapeutic
applications.

1.6 Therapeutic Applications: Magneto Hyperthermia
Magneto hyperthermia is a noninvasive technique that devastates diseases tissues, for instance,
cancer cells, by transferring fatal dose of heat to the actively-targeted site of interest upon
exposure to an oscillating external magnetic field while preserving surrounding vicinity of
healthy tissues from any significant damage.
1.6.1 Physicochemical Principles of Magneto Hyperthermia
As previously explained, the hysteresis loop of macroscopic, bulk, ferromagnetic materials (see
Figure 2.22) is primarily responsible for the heat generation when an external oscillating
electromagnetic field is applied to a colloidal system of magnetic material. Upon exposure to a
properly intense alternating field, the material will continuously get magnetized and
demagnetized according to its hysteresis loop curve while each cycle leads to the release of
energy in the form of heat.
In sharp disparity, upon application of an external oscillating magnetic field to
superparamagnetic nanoparticles, which are intrinsically in constant rotation due to their very
small thermal energy barrier, the heat generated results from two different relaxation
mechanisms (i) Néel and (ii) Brownian relaxations. In case of Néel’s, the produced heat is due to
the occurrence of rapid alteration in the orientation of the magnetic moments correlated to its
crystal lattice’s arrangement – i.e. it is an internal dynamic process. The continuous change of
the directions is hindered by the anisotropic energy barrier of the crystal lattice which will
typically tend to direct the magnetic domains in the most energetically favorable orientation.
Heat loss in the form of thermal relaxation arises as a result of overcoming these energy barriers
(Kumar & Mohammad, 2011). In case of Brownian relaxation, the produced heat is due to the
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physical rotation of the particles themselves in the surrounding medium – i.e. it is an external
dynamic process, in which the rheological properties of the medium (i.e. viscosity and fluid
dynamics) where the magnetic nanoparticles MNPs are placed will, to a great extent, affect the
amount of the heat generated since the heat dissipation is mainly created by the frictional forces
created during the physical rotation (Kumar & Mohammad, 2011). Figure 2.27 illustrates the
two different mechanism of relaxation. In case of the internal dynamic Néel relaxation mode the
crystal lattice configuration of the nanoparticles rotate so as to align themselves according to the
external field directions while overcoming the crystal lattice energy barrier. In case of the
external dynamic Brownian relaxation mode, the entire particle will continuously tend to align
itself in accordance to the external field which typically produce a localized friction forces with
the surrounding media and subsequently produces heat (Mornet et al., 2004).

Figure 2.27. Néel and Brownian Relaxation Mechanisms (Mornet et al., 2004)
The specific absorption rate SAR of MNPs represents the slope of the time-dependent
temperature curve. The SAR is a useful parameter to contrast the heating capability of different
magnetic nanoparticles. In addition, it is used for evaluating their selection.
𝑆𝑆𝑆𝑆𝑆𝑆 = c

𝑑𝑑𝑑𝑑
𝑑𝑑𝑑𝑑

Where: c corresponds to the heat capacity of the solution, T for temperature and t for time.
A new term which was only proposed in 2009, and is not yet well-known defined as
intrinsic loss power ILP, the advantage of the new term that it lacks the extrinsic parameters –
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i.e. frequency and field amplitude. Therefore, the inherent heating ability of the nanoparticles can
be expressively compared. The ILP is more suitable for superparamagnetic nanoparticles and is
also valid for frequencies up to 900 kHz, this range is commonly applied for most biomedical
applications (Kallumadil et al., 2009; Kumar & Mohammad, 2011).
Multifunctional graphitic magnetic nanomaterials (e.g. cobalt and iron) have been
synthesized by different methods. For instance, flame spray (Grass et al., 2007; Herrmann et al.,
2009), microwave arch discharge (Hsin et al., 2008; Liang et al., 2008), chemical vapor
condensation/deposition (Wang et al., 2003) and ultrahigh sonic power (Nikitenko et al., 2001).
All synthesized particles were directly administered to their targets (e.g. cancerous HeLa cell
cultures) and lacked the targeting moieties which in general hindered the impracticability of such
nanostructures and severely reduced their ability of reaching certain diseased spots where direct
injection would not be possible. After a proper incubation time, usually 24 hours, it was found
that according to their size ranges, the carbon-coated nanomagnets were up-taken inside various
sub-compartments of the target cells. Electromagnetic radiation of radiofrequency ranges 1001000 kHz typically applied to cell cultures due to their high penetrability (Young et al., 1980)
and high bio-tolerance (Nikiforov, 2007). In most of the cases, it was found that the graphitic
materials are strong absorbers of the exposed radiation, such absorbance was reflected in an
elevated localized heating inside the diseased cells. In addition, the nanoparticles were found to
induce localized damage of the cellular DNA and various membranes integrity, which was
reflected in the stimulation of cellular apoptosis (Mahmood et al., 2009; Xu et al., 2010). Even
so, various MNPs are FDA approved while others are still in the process of getting approved.
Table 2.14. Commercially Available MNPs Currently FDA Approved (Cole et al., 2011)
Pre-Clinical Agent

Commercial Name

Target

Status

AMI-25

Ferumoxide, Feridex, Endoderm

Liver

Approved

OMP

Abdoscan

Bowel

Approved

AMI-227

Combidex, Sinerem, Ferumoxtran

Lymph Node

Phase III

CODE 7228

Feraheme, Ferumoxytol

Vasculature

Phase II
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1.7 Nano-Magnetism from Ferro to Superparamagnets: The Epilogue
Momentous development has been made with respect to magnetic nanostructures platforms for a
huge range of magneto hyperthermia applications, particularly for cancer treatment. However,
there are still gaps in the awareness and technical capacity which avert such progresses from
being transferred from the lab-bench-tops to the bed-sides in clinic. In addition, limitations exist
for targeting effectiveness, predominantly with respect to active/magnetic targeting.
Furthermore, there has been recently more focus on understanding the biocompatibility and
cellular cytotoxic concerns for the implementation of nanotechnology in biomedical theranostics
fields. The majority of the currently ongoing studies still limited to be conducted only for in vitro
diagnostic applications, whereas, meticulous testing still need to be conducted for in vivo
diagnostic and therapeutic applications as well.

2

Construction and Radioactive Labeling of sdAbs-Fe@C-MNPs Conjugate

Thanks to the particular properties of single domain antibodies, they have high potential for
immuno imaging. A technique has recently been developed at the In vivo Cellular and Molecular
Imaging (ICMI) Laboratory of the Nuclear Medicine Department, UZ Brussels, to generate
highly specific radiotracers based on sdAbs (Vaneycken et al., 2011). The technique takes
advantage of the His-tag that these recombinant molecules contain to form a coordination bond
with Tri-carbonyl Metastable Technetium [99mTc(CO)3(H2O)3]+ which is used for obtaining high
definition images with the aid of single-photon emission computed tomography SPECT (Xavier
et al., 2012).
Another interesting technique in imaging is active/magnetic directing of magnetized
tracers to a specific site of interest within the body – i.e. organ or sub-organ’s location of interest,
using an external focalized magnetic field. In view of a better trespassing, and penetrability, of
these markers through physical boarders, the main aim was to bring this technique to the nanoscale. Therefore, a method to conjugate sdAbs to nanosized magnetic graphene-coated particles
has been developed at Faculty of Science and Bio-engineering, Vrije Universiteit Brussel (VUB)
in collaboration with School of Science and Engineering (SSE), The American University in
Cairo (AUC). For this purpose, carbon-coated metallic Iron nano magnetic beads of an average
diameter 50 nm and exhibiting terminal carboxyl functional groups are conjugated to sdAbs. The
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hereby applied coupling is based on the formation of peptide bonds using water-soluble 1-Ethyl3-(3-Dimethylaminopropyl)Carbodiimide (ECD) and N-Hydroxysuccinimide (NHS).

2.1 Applied Chemistry
2.1.1

General Principle

The Fe@C-MNPs conjugation reaction is based on the formation of peptide bonds by
condensation reaction of terminal carboxyl groups formed on the surface of the MNPs with the
amino groups, particularly from lysine, of the sdAb. On the other hand, the chelating of
[99mTc(CO)3(H2O)3]+ is specifically directed to the (His)6 tag of the sdAbs to form a strong
coordination bond. In both reactions, amine groups are involved, where the differentiation
between histidine and non-histidine coupling is achieved by conducting two consecutive
reactions at different pH values. Indeed, the residue of histidine is an imidazole containing
molecule in which the double bound nitrogen atom in the aromatic ring is protonated at pH ≤ 6.
As a consequence, there would be no nucleophilic attack on the carbon of a carboxyl group at pH
lower than 6. Figure 2.28 illustrates all the protonation states of the histidine residues at different
pH values.

Figure 2.28. Protonation States of Histidine at Different pH Values (Li & Hong, 2011)
In sharp contrast, the amino groups of lysine residues are still unprotonated at ≤pH6,
and peptide bonds between terminal functional carboxyl groups of the Fe@C-MNP and the
lysine amino groups of a protein can be formed. The coupling system generated between the
water-soluble carbodiimide (EDC) / N-hydroxysuccinimide (NHS) has its optimum at (pH 5.5).
The hereby presented procedure consists of (a) first performing the condensation reaction at (pH
5.5) with the EDC/NHS system, directed to non-histidine residues (i.e. Lys) amines, then (b)
followed by the His-directed radioactive labeling of the sdAb-Fe@C-MNPs complex
with[99mTc(CO)3(H2O)3]+ at relatively higher pH value (i.e. pH 7.4) and temperature 50°C.
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Noteworthy, both of the sdAbs as well as carboxylated magnetic beads remain highly stable
under in these harsh conditions.
2.1.2

Preparation of His6-Tag Anti-GFP and Ni-NTA Magnetic-Beads Conjugate

The binding affinity of the conjugated sdAb was examined through performing a simple, and
straightforward, conjugation between the (His)6-taged sdAb (e.g. anti-GFP sdAb) and the nickelnitrilotriacetic acid Ni-NTA functionalized magnetic beads from QuickPick™ IMAC. The
remaining GFP content is typically estimated through measuring the fluorescence peak which
exists at a wave length of about 488 nm. The conjugation conditions of the preliminary test are
now used as a basis for this protocol, but should be further optimized.
2.1.3

The Non-His Conjugation of sdAb to Fe@C-MNPs

The non-His conjugation between the antibodies and the graphene-coated magnetic nanoparticles
is performed with a classical condensation reaction using carbodiimide as intermediate, whereby
the carboxyl groups of the magnetic beads react with the primary amine groups (i.e. terminal or
intermediate groups) of the sdAb in order to form a peptide bond.

Figure 2.29.General Reaction of the Formation of a Peptide Bond. Starting from a carboxyl
group and a primary amine group, using a carbodiimide, which is taking part in the reaction but
does not appear in the final product (Li & Hong, 2011)
Figure 2.30 illustrates the reaction mechanism involves the presence of carboxylic group
from the first molecule and the EDC crosslinker in order to form the first unstable intermediate
(o-Acylisourea) which in the presence of N-hydroxysuccinimide (NHS) is transformed into the
corresponding urea and a more stable carboxy-succinimide ester. The latter reacts spontaneously
with primary amines from another molecule 2 to form the peptide bond.
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Figure 2.30. Carboxyl-to-Amine Crosslinking Using the Carbodiimide EDC and Sulfo-NHS.
The formed carboxy-succinimide ester reacts spontaneously with primary amines, leading to the
aimed peptide bonds (Pierce, 2012)
The hereby described procedure activates the carboxyl groups of the magnetic beads with
the water soluble EDC and NHS. This system has an optimum performance at (pH 5.5), a
condition where histidine molecules do not react.
2.1.4

The His-Tag Specific Labeling of sdAb with 99mTc

His-tagged sdAbs are particularly suited for

99m

Tc-labeling via tricarbonyl chemistry. Indeed,

histidines have proven to coordinate efficiently to the tricarbonyl core of

99m

Tc-tricarbonyl

(Garayoa, 2002; Xavier et al., 2012)

Figure 2.31. Technetium Labelling of a Biomolecule Through the Tc-tricarbonyl Synthon
(Garayoa, 2002)
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Crystallography studies have also proofed that the His-tag on sdAbs is located on the
opposite side of the paratope (Vincke et al., 2009). Hence, it minimizes the risk of interference
with antigen-binding capability. Finally, the high thermal and chemical stabilities have been
recognized as essential criteria for efficient complexation of the 99mTc-tricarbonyl to His-tagged
antibody fragments (Broisat et al., 2012), and these high stability properties are a typical feature
of SdAb (Dumoulin et al., 2002).
The complete labeling procedure has been described by Catarina Xavier et al., and starts
with the generation and purity assessment of the

99m

Tc-tricarbonyl precursor. Afterward, it is

followed by a set of straightforward procedures for the sake of complexing the precursor with the
His-tagged sdAbs. Finally, various ways are applied to evaluate the radiochemical purity of the
obtained sdAb-Fe@C-MNP derived radiotracer conjugate (Xavier et al., 2012).

3

Materials and Methods

3.1 Materials
3.1.1 Reagents and Buffers
Table 2.15. Reagents and Buffers used in this research
Reagents and Buffers

Composition

Supplier

Carboxylated Magnetic Beads

25-50 nm Fe@C-MNP

TurboBeads®

concentration 30 mg/mL
suspended in 5 mL H2O
5 x 1013 Particles/mL
8.7 x 1017 mmol (-COOH) 3/ Particle
QuickPick™ IMAC

metal affinity kit for proteins

Bionobile

IMAC Magnetic Particles

IMAC magnetic particles in PBS

Bionobile

buffer adjust pH 7.0, 1M NaCl,
0.05 % Tween-20, 0.02 % NaN3
IMAC Regeneration Buffer

Aqueous NiSO4 solution,

Bionobile

0.05 % Tween-20, 0.02 % NaN3

3

The beads are functionalized with 2-Phenylethylamine and 3-Phenylpropanoic acid groups respectively
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Reagents and Buffers

Composition

Supplier

IMAC Imidazole Buffer, 500

500 mM imidazole in PBS buffer

Bionobile

mM

adjust (pH 7.0), 0.02 % NaN3

IMAC2x Wash Stock Buffer

PBS buffer (pH 7.0), 1 M NaCl,

Bionobile

0.05 % Tween-20, 0.04 % NaN3
IMAC Wash Buffer 1

1700 µL IMAC2x wash buffer

Bionobile

1700 µL H2O
IMAC Wash Buffer 2

1700 µL IMAC2x wash buffer

Bionobile

135 µL Imidazole buffer 500 mM
IMAC Wash Buffer 3

1700 µL IMAC2x wash buffer

Bionobile

270 µL Imidazole buffer 500 mM
680 µL 5 M NaCl
750 µL H2O
IMAC Elution Buffer

20 mM Tris-HCl (pH 8.0), 250 mM

Bionobile

NaCl, 300 mM imidazole,
0.05 % Tween-20, 0.02 % NaN3
MES Buffer

1.06 g MES

(2-(4-Morpholino)

dissolve in 90 mL H2O

ethanesulfonic acid

adjust pH to 5.5

Sigma-Aldrich

adjust final volume to 100 mL
PBS/Tween Buffer

PBS buffer

Sigma-Aldrich

adjust pH to 7.4
0.05 % Tween-20
EDC Solution

10 mg/mL EDC in MES buffer

Sigma-Aldrich

NHS Solution

10 mg/mL NHS in MES buffer

Sigma-Aldrich

Lyophilized kit IsoLinkTM

4.5 mg of sodium boranocarbonate

Covidien

2.85 mg of sodium tetraborate.10H2O
8.5 mg of sodium tartrate.2H2O
7.15 mg of sodium carbonate, pH 10.5
Hydrochloric Acid

1 M HCl in H2O

Sigma-Aldrich

His-tagged anti-VCAM sdAb

1 mg/mL sdAb in PBS buffer

CMIM, VUB
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Reagents and Buffers

Composition

Supplier

His-tagged anti-HER2 sdAb

1 mg/mL sdAb in PBS buffer

CMIM, VUB

His-tagged anti-GFP sdAb

1 mg/mL sdAb in PBS buffer

CMIM, VUB

eGFP protein

1 mg/mL eGFP in PBS buffer

CMIM, VUB

Instant Thin Layer

acetone

Sigma-Aldrich

Chromatography ITLC Eluent
3.1.2

Equipments and Consumables

Table 2.16. Equipments and Consumables used in this research
Equipment/Consumable

Supplier

99

Drytec, GE Healthcare

Mo/99mTc Generator

Ventilated hood with leaded-shield

GE Healthcare

PickPen® Magnet

Bionobile

®

PickPen tips

Bionobile

Vivaspin® HY 5000

VIVAPRODUCTS

Water bath

Eppendorf

Polycarbonate microtubes

Sigma-Aldrich

Silica gel impregnated glass fiber sheets

Pall Corporation, Life Sciences

Gamma counter

Drytec, GE Healthcare

Ultrasonic homogenizer

Hielscher

3.2 Methods
3.2.1 Preparation of His6-Tag Anti-GFP sdAb and Ni-NTA Magnetic-Beads Conjugate
The main motive behind performing this experiment was to confirm (a) the preservation of the
binding affinity of the conjugated sdAb and (b) the absence of any shielding or masking effect on
its active paratopes. In order to optimize the ratio between anti-GFP and Ni-NTA magnetic beads
(i.e. QuickPick™ IMAC) during conjugation, different concentrations of anti-GFP for a constant
amount of magnetic beads were tested.
Procedure
1. In order to avoid any unspecific binding of the His-tagged eGFP protein, the protein
sample was washed with IMAC wash buffer 1.
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2. Tubes were numbered and filled up with sample/solutions as follows:


Tube 1: 100 µL IMAC Magnetic Particles



Tube 2: 400 µL IMAC Regeneration Buffer



Tube 3: 400 µL IMAC Wash Buffer 1



Tube 4: 300 µL eGFP Protein Sample



Tube 5: 400 µL IMAC Wash Buffer 2



Tube 6: 400 µL IMAC Wash Buffer 3



Tube 7: 50 µL IMAC Elution Buffer

Caution: Mix the IMAC magnetic particles suspension thoroughly before pipetting into
microtubes, in addition, higher yields can be obtained by optimizing the incubation time.
3. The PickPen® was dressed up with its tip and immersed in tube 1 to collect all the
magnetic beads, then, released into tube 2 with gentle mixing.
4. The magnetic beads was collected from tube 2 and released into tube 3 and gently
mixed using the PickPen® tip.
5. The magnetic beads were collected from tube 3 and transferred to tube 4 where they
were incubated for 15 min. The solution was mixed occasionally to avoid
sedimentation.
6. After incubation, the beads were collected and washed in tube 5 by gentle mixing for
at least 10 sec, followed by further washing in tube 6 for at least 10 sec.
7. Finally, the washed beads were collected and transferred to tube 7 (containing the
elution buffer), mixed thoroughly and incubated for at least 2 min. The solution was
mixed occasionally to avoid sedimentation.
8. After incubation, the magnetic beads were collected and discarded and the purified
His-tagged protein was transferred into new microtube.
9. The fluorescent peak of the remaining solution from tube 7 was measured at OD448nm
using Nanodrop® spectrophotometer.
3.2.2

Preparation of sdAb and Carboxylated Fe@C-MNPs Conjugate via EDC/NHS

Based on the above optimization test, a ratio of approximately 10/1 weight/weight is considered
between the Fe@C-MNPs magnetic beads and the sdAb. That is to say, 50 µL magnetic beads
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suspension (about 1.5 mg magnetic beads) should couple to 50 µg of sdAb (i.e. 50 µL anti-eGFP,
anti-VCAM and anti-HER2 sdAbs).
Procedure
1. The carboxylated Fe@C-MNPs magnetic beads was homogenously dispersed using a
sonicator with 10 x 5 sec pulses, with interval times of about 10 sec.
2. After sonication, the beads were brought up to room temperature, then 50 µL of the
beads suspension was transferred into a new 2 mL polycarbonate microtube
containing 200 µL MES buffer for washing via gentle mixing using the PickPen® tip.
3. The beads were collected and washed again after being transferred into another
microtube containing 200 µL of MES buffer. Finally, the beaded were collected and
transferred into a microtube containing 50 µL of MES buffer.
4. An equal volume of EDC solution was added – i.e. 50 µL EDC. Then immediately
followed by addition of another 50 µL NHS solution. Finally, the mixture was
incubated at room temperature for 20 min with continuous gentle agitation.
5. The as-produced sdAbs (i.e. sdAb in PBS buffer) were prone to change their buffer
into MES buffer via several centrifugation cycles using Vivaspin® HY 5000 tubes,
then concentrated up to a final concentration of about 1.0 mg/mL.
6. After incubation, the activated magnetic beads were collected and transferred into the
microtubes containing 50 µL of each sdAb. The mixture was incubated with
continuous shaking for about 30 min.
7. After incubation, the conjugated beads were collected and washed 3 times in 3
consecutive microtubes containing 200 µL PBS/Tween. Finally, beads were collected
and redispersed via vortex in 100 µL PBS/Tween.
8. In order to confirm the preservation of the binding affinity of the sdAb conjugated to
the carboxylated magnetic beads via EDC/NHS method. All the conjugated anti-GFPFe@C-MNPs were collected and transferred into new microtube containing eGFP
protein sample of the same concentration (i.e. Tube 4) as described earlier.
9. The fluorescent peak of the remaining solution from tube 7 was measured at OD448nm
using Nanodrop® spectrophotometer.
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3.2.3

Radioactive Labeling of sdAb-Fe@C-MNP Conjugate

Utilizing the well established technique of radioactive labeling of the single domain antibodies
(Xavier et al., 2012) paved the road for the subsequent labeling of the entire conjugate – i.e.
single domain antibodies and the graphene-coated magnetic nanoparticles. Such radio-labeled
bio-nanostructure would present a very informative tool for a wide range of applications, for
instance: (a) confirming and optimizing the EDC/NHS bioconjugation and (b) enabling the
characterization and imaging of the actively targeted magnetic nanoparticles which will
possibility impact both in vitro and in vivo theranostic applications under the gamma camera and
MRI machines respectively. The purpose of this section is to show in step-by-step manner the
easy way of preparing the radioactive precursors followed by the radioactive labeling with 99mTcTricarbonyl, and then afterwards, instant thin layer chromatography analysis for assessment of
radiochemical purity of labeled conjugate and finally the characterization of the capability of
magnetic targeting under gamma camera will be addressed as well.
A. Preparation of 99mTc-Tricarbonyl Precursor
Procedure
1. Exactly 1 mL of the
99

TcO4- solution which was previously prepared by the

99m

Mo/99mTc generator, with radioactivity of about 0.74 – 3.7 GBq was added to the

IsoLink™ kit.
2. The mixture was incubated at 100 °C for about 20 min.
3. After incubation, the reaction mixture was cooled down in water bath and brought to
room temperature.
4. Finally, the pH of the reaction mixture was adjusted to 7.4 using 1 M HCl.
B. Radioactive labeling of sdAb-Fe@C-MNP Conjugate with 99mTc-Tricarbonyl
Procedure
1. Approximately, 50 µL of the sdAbs and free Fe@C-MNPs were added to about 450
µL of fac-[99mTc(CO)3(H2O)3]+ at a pH 7.4.
2. About 250 µL of the sdAb-Fe@C-MNP conjugate in PBS was added to about 250 µL
of fac-[99mTc(CO)3(H2O)3]+ at a pH 7.4.
3. The reaction mixtures were incubated at 50 °C for about 60 - 90 min.
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Caution: The temperature of incubation depends on the thermostability of the sdAb, it is
always recommended to determine, in advance, the melting temperature (Tm) of sdAb to
be labeled.
4. The labeled conjugate was separated from the free

99m

Tc-Tricarbonyl and

TcO4-

99m

via PickPen® or conventional magnet bar.
C. ITLC analysis for Assessment of Radiochemical Purity
Procedure
1. About 2 µL of the

99m

Tc-Tricarbonyl labeled conjugate solution was added onto a

15mm x 200 mm silica gel impregnated glass fiber sheet.
2. The ITLC chromatogram was developed in acetone.
3. The distribution of radioactivity was analyzed by scanning with a γ-radiation TLC
scanner or counting the strip cut in 3 parts (i.e. application point, middle, solvent
front) in a dose calibrator or gamma counter. Knowing that, the
precursor and the

99m

Tc-Tricarbonyl

TcO4- reveal a retention factor value (Rf) of 1, whereas, the

99m

99m

Tc-Tricarbonyl-Conjugate has an Rf of about Zero.

3.2.4

Magnetic Targeting of the Radio Labeled sdAb-Fe@C-MNP Conjugate

The application of an external magnetic field by using a commercial standard magnet bar (i.e.
≤
0.55 Tesla) was performed under a gamma camera for two main reasons:


Confirming the attachment of the radiolabeled sdAb to the graphene-coated magnetic
nanoparticles.



Proofing the concept of magnetic targeting function for the entire conjugate when it is
placed in a phosphate buffered saline at the natural physiological criteria.

Procedure
1. The radiolabeled conjugate was transferred to a PBS/Tween (pH 7.4) filled 100mm
dia. x 15mm H round Petri dishes and 50 mL Falcon tubes.
Caution: All the radiolabeled solutions must be handled with great care to avoid
radioactive contamination.
2. Place the Petri dishes and the Falcon tubes under a gamma camera for capturing
images at static conditions for at least 4 min.
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3. An external positioned magnet (i.e. < 0.55 Tesla) was placed while running the
gamma camera and continued capturing images.
4. The magnet was removed and the gamma camera continued capturing image after
removal for at least 1 min.

4

Results and Discussion

4.1 His6-Tag Anti-GFP sdAb and Ni-NTA Magnetic-Beads Conjugate
After conjugating the His6-tagged anti-GFP to the Ni-NTA magnetic beads from QuickPick™
IMAC the concentration of the eGFP protein content was measured using Nanodrop
spectrophotometer at OD280nm and OD488nm.
Table 2.17 illustrates the initial and final concentrations and absorbance values of the eGFP
proteins after purification using NI-NTA magnetic beads.
Table 2.17. Concentration of eGFP Proteins before and after Magnetic Purification
Initial Conc.

Initial Absorb.

Final Conc.

Final Absorb.

(mg/mL)

(a.u.) 4

(mg/mL)

(a.u.)

eGFP – 25 µL

0.21

0.449

0.00

-0.206

eGFP – 50 µL

0.47

0.945

0.14

0.291

eGFP – 100 µL

0.95

1.798

0.29

0.621

Protein

In addition, the fluorescent finger print of the eGFP protein was reduced in equivalence to the
above results. Finally, the optimum obtained results came from using a 50 µg of sdAb per 1.5 mg
(i.e. 50 µL) of magnetic beads.

4.2 Preparation of Anti-GFP sdAb and Fe@C-MNPs Conjugate via EDC/NHS
The optimized set-up from the previous experiment was used to evaluate the conjugation’s
efficiency of the anti-GFP sdAb conjugated to 25-50 nm Fe@C-MNPs via EDC/NHS method.
Table 2.18 represents the initial and final concentration of the eGFP protein after magnetic
purification using the PickPen® magnet.
4

Absorbance Units
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Table 2.18. Concentration of eGFP Proteins before & after Fe@C-MNPs Magnetic Purification
Protein
eGFP – 50 µL

Initial Conc.

Initial Absorb.

Final Conc.

Final Absorb.

(mg/mL)

(a.u.)

(mg/mL)

(a.u.)

0.44

0.913

0.12

0.314

In the same way, the fluorescent finger print of the eGFP protein at OD448nm was reduced in
equivalence to the obtained results. Certainly, both of the Ni-NTA magnetic beads as well as the
Fe@C-MNP were able to get conjugated to the anti-GFP sdAb with equal efficiency. In addition,
with the aid of an external magnet they could, powerfully, collect their specific target antigen
(i.e. the eGFP protein) from the PBS buffer. In conclusion, the EDC/NHS conjugation did not
affect the antigen binding capacity of the sdAbs and preserved their immunogenicity.

4.3 Radioactive Labeling of sdAb-Fe@C-MNP Conjugate
After the radioactive precursor was prepared it was incubated with the reagents as follows:


50 µL Free Fe@C-MNP + 450 µL [99mTc(CO)3]7+



50 µL Anti-HER2 sdAb + 450 µL [99mTc(CO)3]7+



50 µL Anti-VCAM sdAb + 450 µL [99mTc(CO)3]7+



250 µL Anti-VCAM sdAb-Fe@C-MNP Conjugate + 250 µL [99mTc(CO)3]7+



250 µL Anti-HER2 sdAb-Fe@C-MNP Conjugate + 250 µL [99mTc(CO)3]7+

Table 2.19 illustrates the initial and final activities of the free graphene-coated magnetic
nanoparticles, as well as, those of the different prepared conjugates in accordance to their
incubation times.
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Table 2.19. Radioactivity of the Radiolabeled Reagents and Conjugates
Initial Activity

Final Activity

Incubation

Labeling

(µCi) 5

(µCi)

Time

(%)

Free Fe@C-MNP

2.99

0.34

2 hr 03 min

11.4

α-VCAM Conjugate

2.83

0.685

2 hr 29 min

20

α-HER2 Conjugate

2.75

0.89

2 hr 56 min

25

Free α-HER2 sdAb

4.68

3.84

1 hr 46 min

> 99

Free α-VCAM sdAb

5.05

4.1

1 hr 47 min

≈ 93

Reagent/Conjugate

The naked graphene-coated magnetic beads showed 11.4% labeling capacity which might be
considered as non-specific binding to the particles, however, the radioactivity of the magnetic
particles will be added to the whole conjugate and will serve for the benefit of the
tracing/imaging experiments.

4.4 Magnetic Targeting of the Radio Labeled sdAb-Fe@C-MNP Conjugate
After transferring the radiolabeled content of the conjugated sdAb to Petri dishes and Falcon
tubes filled with PBS/Tween, they were placed under dynamic gamma camera (i.e. 1 frame/s) for
characterization and visualizing the effect of placing an externally position, commercially
standard, magnet bar of an intensity < 0.55 Tesla. Figure 2.32A represents the qualitative
analysis of the initial static condition of the fully dispersed radiolabeled sdAb conjugates (i.e. αVCAM- and α-HER2-Fe@C-MNP conjugates), while Figure 2.32B represents the focalization
effect of placing an external magnet bar. The increase in intensity is mainly concluded by the
attraction of the dispersed magnetic particles to the externally positioned magnet, which confirm
the binding between the radiolabeled single domain antibody and the graphene-coated metallic
Iron magnetic nanoparticles.

5

1 microcurie (µCi) = 37 kilobecquerel (kBq)
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Figure 2.32. Qualitative Analysis of Magnet Focalization of the Radiolabeled Conjugate. A.
Represents the initial static condition, while, B. Represents the focalization effected obtained
after application of the external magnet.
Figure 2.33 illustrates the quantitative analysis of the focalization effect in the Petri dish,
in the beginning, the magnet was placed after one minute of capturing time, a fast focalization
took place (i.e. from ≈ 2.5% to 20%), then followed by slow increase over extra four minutes in
the radioactivity till it reached about 32% of the total radioactivity sensed in the entire containing
medium.

Figure 2.33. Quantitative Analysis of Magnet Focalization of the Radiolabeled Conjugate
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5

Conclusion

The properties of the single domain antibodies were combined with the vast growing
nanotechnology. In general, any diagnostic and/or therapeutic application will require certain
predefine multifunctional criteria, above and beyond is the presence of a smart targeting moiety
which is able to deliver the attached loads to its corresponding site with minimal/insignificant
non specific targeting. In the current study, sdAbs were selected to represent the specific
targeting agent and the nanomagnetism was selected to express the superiority of
nanotechnology in constructing such a system of high biocompatibility and easy-tailored
physiochemical properties which can be predesigned to serve for diagnostic as well as
therapeutic applications.
The distinctive inherent ferro and superparamagnetic properties combined with the
superior chemical, thermal and biological stabilities of the multilayered graphene-coating have a
wide range of novel and efficient tools for highly multipurpose applications – i.e. diagnostic and
therapeutic fields. Worth mentioning, their brilliant properties enable them to effectively impact
other different fields as well – i.e. environmental, agricultural, chemical and industrial. The
implementation of the currently available simple and mass-scalable synthetic methods would
provide high control over size and shape which will supply economic and eco-friendly
candidates for future research works. Finally, the development of novel functionalization
protocols together with new-fangled smart targeting ligands – e.g. sdAbs, will sincerely lead to
the generation of a new epoch of scientific researches which will pave the road for a new era of
noninvasive and side-effects’ free theranostic means.
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CONCLUDING REMARKS AND FUTURE CHALLENGES
Schistosomiasis: the disease, the severity of the gap in the present intensity of applied research
workloads and the scarce sensibility of withdrawn attention incited the authors of this research
work to conduct the current research. Neglected tropical diseases as “Bilharziasis” infects at least
200 million individuals in 75 countries, while 120 million people are symptomatic patients, a
further 600 million people are still exposed to infection and are potentially victim of this parasite
(WHO, 2010), which causes brutal debilitating and incapacitating illness in millions of human
and cattle. The annual death of Schistosomiasis was recently estimated by 150 – 200 thousand
people every year, adding to that the drastic impact on economical and nutritional aspects
(Blyther, 2011).
The development of a novel theranostic agent was the main target, in order to get it
accomplished the single-domain antibody technology was selected to design a stable and
efficient targeting moiety. In addition, the implementation of the vast growing nanotechnology
was established via two major joint aspects (a) Nanobodies® technology, which, by itself, can
afford a serological and therapeutic tool and (b) Graphene-coated magnetic nano-system, which
can provide a complementary diagnostic and therapeutic function. The distinctive combined
properties (i.e. high affinity, thermal and chemical stability, efficient synthesis, plus the
synergistic active and magnetic in vivo/in vitro targeting ability) of the pre-designed system are,
so far, confined in a nanoscale dimensions which sequentially added a wide-range of theranostic
possibilities and applications.
The research described in this thesis resulted in the following methodological novelties:


Nanobodies® against two different Schistosoma mansoni antigens, gut specific
antigen and excretory-secretory antigen,



Active sdAb-Graphene-Coated-Nanomagnet Bioconjugate,



99m

Tc Labeled active conjugate.

The research described in this thesis led to the following important biological
conclusions:


SmCB antigen was recognized as a potent immunogenic antigen and could
elicit proper immune response in Camelidae’s which subsequently lead to the
production and purification of antigen-specific sdAbs binders,
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The bioconjugation of sdAb-Fe@C-MNP via EDC/NHS method showed a
high preservation of the binding affinity of the attached Nanobodies®,



The radiolabeled active bio-nano-system could successfully be externally
directed through a simple magnetic targeting process.

The number of reports dealing with bio-nanotechnology applications in different fields
clearly indicates that this class of bio-nanostructure system represents an important tool for
research as well as biotechnological uses, particularly theranostic ones. Despite the advantages of
single domain antibody in terms of unique structural features, stability, and production costs the
technology has taken almost twenty years and yet not largely popular in the scientific area. Part
of the problem comes from the pretty restrictive intellectual property policy introduced by
Hamers’ patents which has probably prevented other contributors from participating in the
development. In addition, there are quite a lot of technical challenges that still need to be studied
in a systematic way, at the recombinant antibody panning level, plus, the level of the pre and post
production strategies. For instance:


Although Nanobodies® usually exhibit high expression yield, inadvertently, those
of high binding affinity may suffer from very low expression.



Some of the developed sdAbs may show excellent performance, yet, lack stability
upon prolonged storage (e.g. dimerization), which necessitates an afterward
genetic engineering intervention.



The clearance time is a very crucial factor that it may act as a double-edged
sword, several techniques need to be developed to control the optimal blood
circulating time.



The undesired accumulation in kidney still requires further investigation for
finding the reason and discovering appropriate solutions.



Tailoring into pluripotent constructs of Nanobodies® and their fusion derivates as
well as their heterogeneous conjugate systems.

Finally, the single-domain antibody original patents are expiring in the next year along
with the recent accessibility of new libraries, protocols, and vectors suitable for different
theranostic applications. Therefore, it is strongly expected to have an increase of the interest of
both research and industry for this class of sdAb bio-nano-technology in the near future.
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